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Carboxyfullerenes are closed carbon spheres which are being actively pursued 
globally for a wide range of applications. Their inherent properties and ability to be 
functionalized with side-chains results in nearly limitless new chemical structures making 
them ideal platform molecules for new solutions to basic biological problems. In general, 
two classes of fullerenes exist for nanomedicine applications; empty cage and metallo-
fullerenes. The carbon cage (usually C60 and C70) of empty cage fullerenes are anti-
oxidants, thus potential therapeutics for inflammatory diseases. Our discovery that certain 
fullerene derivatives can stabilize and prevent pro-inflammatory mediator release from 
human tissue mast cells make them ideal candidates for diseases controlled by MC 
mediators (e.g. arthritis, asthma, etc.). New research findings using metallo-fullerenes 
with gadolinium inside the carbon cage as diagnostics using Magnetic Resonance 
Imaging for inflammatory diseases suggest metallo-fullerenes are more sensitive than 
current contrast agents, have the ability to be targeted to disease specific biomarkers, and 
are safe. 
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CHAPTER I 
INTRODUCTION 
Fullerenes are carbon spheres presently being pursued globally for a wide range 
of applications in nanomedicine. These molecules have unique electronic properties that 
make them attractive candidates for diagnostic, therapeutic and theranostic applications. 
Herein, the latest research is discussed on developing fullerene-based therapeutics as 
antioxidants for inflammatory diseases and the promise of endohedral fullerenes as new 
MRI contrast agents. The recent discovery that certain fullerene derivatives can stabilize 
immune effector cells to prevent or inhibit the release of proinflammatory mediators 
makes them potential candidates for several diseases such as asthma, arthritis, and 
multiple sclerosis. Gadolinium-containing endohedral fullerenes are being pursued as 
diagnostic MRI contrast agents for several diseases.  
I.1 Fullerenes as a Platform for New Solutions in Several Medicinal Areas 
Empty cage fullerenes (Figure 1.1A & B) have unique electrochemical properties 
and have a wide range of potentially beneficial biologic properties. Another type of 
fullerene can have metals enclosed inside them (Figure 1.1C). Fullerenes have a unique 
cage structure with delocalized p-molecular orbital electrons. This structure confers 
unusual activity in electron transfer systems due to their low reorganization energy, low 
lying excited states (singlet and triplet) and extended triplet lifetimes. Furthermore, the 
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spherical configuration of the planar benzene rings imposes an unusual constraint on 
these p-electron orbitals. The native fullerene cage is insoluble in water and must be 
derivatized (simply meaning moieties or side groups must be added to the carbon cage) in 
order to make them water soluble (compatible in biological systems). The ability of 
fullerenes to be derivatized with side chains provides opportunities to diversify, manipu-
late, and harness the electronic properties of the cage for selected applications. Of course, 
%,-B#C%?)&,.)/*#?%'($.'#)*#-B,*+%'#/A#.B%#-/DE/(*CF'#EB>')-,$#,*C#-B%D)-,$#E?/E%?.)%'G#
including particle size/length, z-potential, molecular weight, surface characteristics and 
solubility, contributing to how they affect biological systems. All too often, results from 
studies examining the effects of fullerenes on biological systems tend to be extrapolated 
to other applications.  
 
 
Figure 1.1.  Representative Fullerene Structures. (A) Empty cage C60 fullerene, (B) 
empty cage C70 fullerene and (C) gadolinium-enclosed C80 endohedral fullerene. 
 
As demonstrated below, each fullerene derivative (FD) must be assessed 
separately depending on the biological application. Even extremely similar FDs can have 
completely opposite results, which stimulates efforts to understand how changing the 
chemical composition and structural arrangement of fullerenes affects molecular 
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interactions at the cellular, tissue and organ system levels. Consequently, their inherent 
properties described in the article, combined with their ability to be derivatized with side 
chains, results in almost limitless new chemical structures, making them ideal platform 
molecules for innovative new solutions to basic biological problems. Fullerenes are one 
of many types of carbon nanomaterials being investigated for next-generation medical 
applications; presently carbon nanotubes are being investigated as drug carriers 
(manipulating their hollow internal core), biosensensors (attaching enzymes to their 
walls) and targeted transporters of drugs [1-4]. The 2D structure graphene is being 
investigated as a drug/gene delivery nanocarrier and targeted cancer therapy [5, 6]. This 
thesis will focus on the applications of both empty cage derivatized and endohedral 
fullerenes for therapeutic, diagnostic and theranostic (combination of diagnostic and 
therapeutic) applications. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
II.1 Fullerenes as Therapeutics 
7($$%?%*%'#B,&%#H%%*#-/)*%C#IA?%%#?,C)-,$#'E/*+%'F#,*C#C%'-?)H%C#D/'.#A?%J(%*.$>#
as antioxidants, although in biological systems they can paradoxically act as both 
oxidants and antioxidants. The generation of free radicals such as reactive oxygen species 
(ROS) and reactive nitrogen species occurs naturally in cells, and their presence at sites 
of disease pathologies suggests they contribute to disease progression. The term free 
radical refers to a molecular species that possesses an unpaired electron, which makes 
them highly reactive. Many of the more common ROS or reactive nitrogen species that 
contribute to oxidative or nitrosative stress in biological systems are free radicals, 
)*-$(C)*+#B>C?/K>$#?,C)-,$'#2LMN6G#'(E%?/K)C%#,*)/*'#2LO
-), and peroxynitrites (ONOO-). 
Other ROS are not free radicals, including singlet oxygen and hydrogen peroxide (H2O2), 
which are considered ROS because they can generate oxygen radicals, such as 
superoxide, via the Fenton reaction. These ROS can react with, crosslink and alter the 
function of many macromolecules. These species can negatively affect a wide variety of 
biological processes; however, in certain situations they can be beneficial to some 
biological processes such as signaling and cellular defenses. Antioxidants (e.g., vitamins 
A and C) are molecules that can eliminate or neutralize free radical electrons. This has 
led to a tremendous amount of research on preventing damage using antioxidants, 
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theorized to, in turn, counteract disease pathologies. Indeed the perceived benefits of 
antioxidants are a widely accepted concept yet their use has been mainly centered on 
over-the-counter supplements for general health and antiaging benefits.  
The carbon cage (usually C60 and C70) of empty cage fullerenes (Figure 1.1) can 
have antioxidant functionality based on its ability to absorb electrons and disperse them 
.B?/(+B#.B%#P5#Q-conjugated structure distributed over its surface. This ability to 
scavenge free radicals has led to their potential as a new way for treating a wide range 
clerosis (MS) [7], neurodegenerative [8], anti-HIV activity [9, 10], cancer [11], radiation 
exposure [12], ischemia [13], osteoporosis [14], general inflammation [15] and selective 
antimicrobial agents against bacteria [16]. Interestingly, mice and rats chronically treated 
with water-solubilized carboxylated fullerenes have significantly extended lifespans 
compared with littermate controls [17, 18]. There are almost endless possibilities for 
adding side groups to the carbon cage to induce functionality, resulting in potential 
,*'R%?'#./#'/D%#/A#D/C%?*#D%C)-)*%F'#most elusive problems. 
 
II.2 Fullerenes as Carriers for Drug and Gene Delivery 
Recently, much interest and focus has been directed towards developing safe, 
targeted and competent transport mechanisms for drugs and genes to cells. This transport 
is often riddled with difficulties as the cellular membrane creates efficient barriers that 
can prevent or slow the uptake of compounds. However, the small size (<5 nm) of 
fullerenes has generated significant interest in the field. Hydrophillic entities can be 
decorated around the fullerene cage, modifying the fullerenes relative insolubility in 
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aqueous solutions. The water-soluble FD can readily cross the cellular membrane without 
damaging cells [8, 19]. These fullerenes can be further modified to become carriers of 
drugs and genes. Evaluated below is some of the present research in which fullerenes 
have been functionalized to become water soluble and utilized as versatile nanocarriers to 
target, treat and prevent disease with high biocompatibility. 
II.3 Ability of Fullerenes to Affect Mast Cell-Driven Allergic Inflammation 
Allergic reactions are the result of B-cell-produced, specific IgE antibody to 
common, normally innocuous antigens. In simplistic terms, mast cells (MCs), peripheral 
blood basophils (PBBs), natural killer cells, T cells and even B cells are responsible for 
driving the initial allergen-inducing reaction through the production of IL-4 and other 
Th2-specific cytokines, which result in IgE sensitization. Re-exposure to the allergen 
triggers an allergic response through the release of inflammatory mediators from MCs 
and PBBs. The IgE produced binds to FceRI on MCs and PBBs, and the release of 
preallergic mediators is induced when two or more IgE molecules are crosslinked with 
the allergen. Indeed, most allergy medications are aimed at neutralizing (antihistamines 
and H1-receptor blockers) or preventing (omalizumab) MC and PBB FceRI responses. 
New research has demonstrated that specifically engineered FDs are taken up and can 
stabilize human tissue MCs, preventing the release of proinflammatory mediators from 
these cells, making them ideal candidates for those diseases controlled by MC mediators 
[20-22]. The ability for FDs to stabilize MC-driven diseases in vitro should translate to 
blocking in vivo, as shown by Dellinger et al. [21]. 
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II.4 Ability of Fullerenes to Dampen Asthma Pathogenesis 
MCs are ubiquitously expressed in tissues and are uniquely able to initiate and 
propagate certain inflammatory responses, as well as offer an interface between innate 
and adaptive immunity [23]. Mice without MCs fail to develop asthma-like pulmonary 
disease when sensitized with less aggressive immunization protocols and challenged with 
aerosolized allergens [24, 25]. However, the strongest evidence that MCs are critical for 
human asthma comes from the many therapeutics used to treat the disease in humans. In 
general, two categories of therapies were developed to control asthma; blocking MC 
activation before it occurs (stabilizers) and blocking MC activation after it occurs. MCs 
are the only cells in the lung that have prestored TNF-1 in their granules that can be 
immediately released upon allergen provocation [26] and blockade of this cytokine is a 
valid target currently being investigated [27]. Therapies that block the effects of MCs 
after activation occurs are well known, commonly used, and include antihistamines and 
H1-receptor blockers. Thus, the importance of MCs in asthma pathogenesis is well 
established, and controlling the amount of mediator release from these cells is a proven 
drug development strategy.  
The role of basophils in asthma is less clear. Their role in allergic disease has 
largely been viewed as redundant to that of tissue MCs. This line of thought, however, is 
changing with evidence that has emerged during the last 15 years. These cells are a 
significant source of the cytokines IL-4 and IL-13, both of which are vital to the 
pathogenesis of allergic disease, including asthma. It has been demonstrated that 
increased levels of basophils were present in the lungs of deceased asthmatics using a 
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basophil-specific antibody developed for immunologically detecting these cell types [28, 
29]. Thus, the infiltration of basophils into allergic lesion sites has sparked greater 
interest in this once overlooked immune cell, both in adaptive as well as innate immunity 
[30].  
There is a strong need for novel therapeutics to treat asthmatic disease; indeed up 
to 55% of patients receiving treatment for asthma have uncontrolled symptomology [31]. 
In some situations, especially in less severe asthmatics, asthma control is achieved with 
the use of nonspecific anti-inflammatories, such as corticosteroids, or by the use of 
antihistamines and leukotriene inhibitors. However, these therapies are generally less 
effective in severe asthmatics or in patients with steroid resistance. As shown below, FDs 
are able to suppress both disease onset and reverse established disease in murine asthma 
models. The latter is especially important as human asthma treatment always involves 
established disease.  
8B%#(.)$).>#/A#75F'#?/$%#)*#,'.BD,#E?%&%*.)/*#,*C#?%&%?',$#-,*#H%#&,$)C,.%C#)*#
mice treated with FDs throughout ovalbumin challenge. Treated animals have 
significantly less airway inflammation and bronchoconstriction compared with untreated 
animals. In fact, total inflammation and bronchoconstriction in the tetraglycolic acid FD-
treated animals are not only significantly reduced, but are similar to that seen in nonsen-
sitized controls (Figure 2.1) [32]. Thus, symptoms of disease are largely reversed in these 
animals. These studies used a model previously shown to utilize MCs [25]. In the 
established disease model, where mice were treated throughout disease development, FDs 
dampened eosinophilia and cytokine levels significantly in the bronchoalveolar lavage 
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(BAL) fluid. Lung sections show massive cellular infiltration in untreated animals, while 
those receiving FDs have minimal cellular infiltration surrounding the airways (Figure 
2.2). This led to reduced airway hyper-responsiveness in FD-treated animals. Thus, FDs 
may be useful in a clinical setting to reverse asthma pathogenesis and limit exacerbation 
of symptoms.  
 
 
Figure 2.1. Characterization of the Novel Fullerene Derivative Tetra-Glycolic Acid 
(C84H12O16). D10: Diameter where 10% of the population have diameters below that 
size; D50: Median diameter where half of the population have diameters below that 
size; D90: Diameter where 90% of the diameters are below that size; SD: Standard 
deviation; TGA: Tetra-glycolic acid. 
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Figure 2.2. Fullerenes Reduce Asthma Airway Hyper-Responsiveness. (A) 
Asthmatic inflammation induced in the lung is inhibited in (B) fullerene derivative-
treated mice compared with (C) NS controls. NS: Nonsensitized; OVA: Ovalbumin; 
PBS: Phosphate-buffered saline; TGA: Tetra-glycolic acid. 
 
While previously published in vitro studies suggested that MC inhibition may be 
the predominant mechanism of FD inhibition [20, 22], in vivo studies suggest multipotent 
effects of these unique compounds. FD treatment reduces the levels of BAL Th2 
proinflammatory cytokines and reduces lung inflammation. While IL-4 stimulates IgE 
production by B cells, IL-5 both recruits and activates eosinophils at the site of 
inflammation. FD treatment significantly reduces both IL-4 and IL-5 in the BAL fluid. 
Additionally, serum IgE levels were significantly reduced following FD treatment.  
Importantly, the use of FD revealed a novel mechanism of action and opened up 
new avenues of research for asthma. Several eicosanoids (EETs) derived from the 
CYP450 pathway are relatively stable, and these molecules were measured in BAL fluid 
samples using mass spectrometry. The EETs are consistently associated with relaxation 
of the bronchi and other in vivo anti-inflammatory actions [33, 34]. The epoxyeicosatri-
enoic acid was consistently upregulated in BAL fluid from FD-treated mice (Figure 2.3). 
Further in vivo studies demonstrated that the EETs play a major role in dampening the 
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asthma phenotype as inhibitors of the EETs prevented the FD-induced modulation of the 
ovalbumin-induced asthma model [32]. Certain EETs stabilize human lung MCs through 
the inhibition of FceRI-mediator release and upregulate the CYP1B1 gene in these cells 
(Figure 2.3). Thought to be produced by lung epithelial and endothelial cells, the EETs 
have been shown to relax histamine-precontracted guinea pig and human bronchi [35, 
36]. Furthermore, they can inhibit the upregulation of VCAM-1, E-selectin, and ICAM-1, 
thus, potentially limiting cellular infiltration of the lung [37]. Consequently, 
epoxyeicosatrienoic acid upregulation plays a significant role in dampening airway 
inflammation and bronchoconstriction in these models. FD upregulation of EETs is a 
novel mechanism for controlling asthma and suggests that strategies that induce the 
production of EETs may be a viable therapeutic strategy for treating asthmatics.  
The efficacy of FD for the treatment of asthma is illustrated through a mechanism 
involving the dampening of eosinophilia and cytokine levels, reducing airway hyper-
responsiveness and upregulating EETs. Thus, FD compounds have the potential to 
become novel therapeutics for the treatment of asthma and pave the way for new research 
efforts focusing on the role of EETs in human disease. 
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Figure 2.3.  Fullerenes Reduce Airway Inflammation by Upregulation of 
Eicosanoids in Bronchoalveolar Lavage Fluid of Mice. (A) FDs upregulate EETs in 
branchoalveolar lavage fluid compared with untreated controls and (B) induce 
CYP1B1 gene inducton. *Statistical significance (p < 0.05). EET: Eicosanoid; FD: 
Fullerene derivative. 
 
II.5 Fullerenes Inhibit Inflammation Caused by Arthritis 
MCs play a critical role in the pathogenesis of synovitis in a murine model of 
rheumatoid arthritis (RA) [38, 39]. The synovium of patients with RA is chronically 
inflamed and characterized by an expanded population of MCs, as in the mouse model. 
9S'#,?%#D,?T%C$>#)*-?%,'%C#)*#*(DH%?#,*C#-,*#-/*'.).(.%#UV:#/A#.B%#%KE,*C%C#
population of total synovial cells. The number of accumulated MCs differs substantially 
from patient to patient, in general, varying directly with the intensity of joint 
inflammation [40-42]. MC mediators (histamine and tryptase) are also present at higher 
concentrations in the synovial fluid of inflamed human joints [43].  
MC degranulation has long been associated with arthritis in several animal 
models, but a critical functional role in the disease was established in the K/BxN mouse 
model [39, 44]. This arthritis model closely mimics human RA via symmetric joint 
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involvement, chronicity, a distal-to-proximal gradient of joint involvement and 
histological features, including synovial infiltrates, pannus, and erosions of cartilage and 
bone [45]. Mice deficient in MCs are highly resistant to arthritis, whereas reconstitution 
with normal MCs restores the wild-type phenotype. Furthermore, degranulation of MCs 
in the synovium is the first event observed histologically, occurring within 1W2 h of 
administration of K/BxN serum [46]. Recent studies reaffirmed a role for MC mediators 
in arthritis [38]. Thus, MCs are a normal cell population within the human synovium and 
have a critical role in the pathogenesis of inflammatory arthritis.  
The mitochondrial electron transport chain is the machinery that orchestrates one 
of the most fundamental chemical processes; the generation of cellular energy from 
oxygen resulting in the fuel that supports all eukaryotic life. However, it is a highly 
sensitive process and, when unbalanced, leads to the generation of free radicals or ROS, 
which have been proposed as being the mechanism underlying many chronic human 
diseases, including MC activation and inflammatory arthritis [47]. Fullerenes can be 
specifically designed to target and accumulate in the internal mitochondrial membrane 
bilayers. Once incorporated, FDs are positioned to neutralize superoxide molecules, 
reactive lipid radicals and radicals that have formed on transmembrane proteins at the site 
where they are generated, thus, inhibiting inflammation [15, 21, 48]. This, in turn, is 
predicted to impact diseases whose pathologies stem from radical injury.  
Therefore, rationally designed FDs were synthesized to significantly block ROS 
production [32, 49]. While it has been shown previously that human MC degranulation in 
response to FceRI stimulation involves ROS [45], it is not clear whether blocking ROS 
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directly blocks degranulation and cytokine production. However, results suggest that 
blocking ROS using FDs in response to an immune complex (a FceRIIA-dependent 
stimuli [50]) parallels inhibition of mediator release. This is in line with previous work 
suggesting that FDs interfere with the generation of mitochondrial-derived ROS [51, 52].  
To investigate the ability of FDs to inhibit arthritis, the K/BxN serum transfer 
model was used. This model induces a rapid and severe synovitis, similar to human RA, 
which is dependent on neutrophils, MCs and macrophages. Its MC dependence was 
revealed from studies in which two strains of mice deficient in this cell type, W/Wv and 
Sl/Sld, were resistant to disease induction following serum transfer [44]. Susceptibility to 
the disease is restored in the W/Wv strain by MC engraftment. Thus, in the K/BxN 
model, MCs function as a link between the serum transfer induction of autoantibodies, 
soluble mediators and other effector populations. By contrast, MC-deficient mice are still 
susceptible to collagen-induced arthritis [53] as well as anticollagen 
antibody/lipopolysaccharide-induced arthritis [45].  
Previously published results have demonstrated the ability of FDs to inhibit MC-
mediated [20, 22] and general inflammation [15]. Given that MCs are the cellular link 
leading to inflammatory arthritis induction and progression, it has been hypothesized that 
blocking MC mediator release could block inflammatory arthritis. The liposome-
encapsulated FD amphiphilic liposomal malonylfullerene (Figure 2.4) was administered 
intraperitonealy before disease induction using the K/BxN model [44], and during the 
course of disease onset there was a striking inhibition of the K/BxN-induced disease 
pathology. After K/BxN serum transfer, the serum-treated mice demonstrated typical 
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synovial hyperplasia, pannus formation and inflammatory infiltrates (Figure 2.5A). By 
contrast, amphiphilic liposomal malonylfullerene-treated animals had less evidence of 
clinical joint inflammation (Figure 2.5B) comparable to nondiseased animals (Figure 
2.5C). 
 
         
Figure 2.4. Characterization of the Novel Fullerene Derivative Amphiphilic 
Liposomal Malonylfullerene (C104H56O12). ALM: Amphiphilic liposomal 
malonylfullerene; D10: Diameter where 10% of the population have diameters below 
that size; D50: Median diameter where half of the population have diameters below 
that size; D90: Diameter where 90% of the diameters are below that size; SD: 
Standard deviation. 
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Figure 2.5.  Fullerenes Attenuate Inflammatory Arthritis of the K/BxN-Induced 
Disease Pathology. (A) Serum-treated mice demonstrated typical synovial 
hyperplasia, pannus formation and inflammatory infiltrates. (B) By contrast, ALM-
treated animals had less evidence of clinical joint inflammation compared with (C) 
nondiseased animals. ALM: Amphiphilic liposomal malonylfullerene. 
 
II.6 Fullerenes as a Potential Therapy for MS 
Experimental allergic encephalomyelitis (EAE) is a rodent model of human MS 
characterized by inflammation in the CNS [54]. Similar to human MS, EAE is associated 
with an early breach of the bloodWbrain barrier (BBB), focal perivascular mononuclear 
cell infiltrates and demyelination leading to paralysis of the extremities. While CD4+ T 
cells have been implicated, the underlying cause of increased vascular permeability that 
facilitates the entry of T cells into the CNS is unknown.  
MC contribution to the pathogenesis of MS has been hypothesized based on their 
presence in CNS plaques of MS patients and the correlation between the number, 
distribution or MC markers in MS or EAE pathology [55]. Further evidence for MC 
involvement in EAE/MS came from studies using MC-deficient mice [56]. The MC-
deficient W/Wv mice exhibited significantly reduced disease incidence, delayed disease 
onset and decreased mean clinical scores when compared with their wild-type congenic 
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littermates. No differences were observed in the T- and B-cell responses between the two 
groups, and reconstitution of the MC population in W/Wv mice restores induction of 
early and severe disease to wild-type levels. These data provide a new mechanism for 
immune destruction in EAE and indicate that MCs may be sentinels of neurologic 
inflammation.  
Previous studies have demonstrated that fullerene-based therapeutics can 
significantly ameliorate EAE [7]. The FD protected neurons from oxidative and 
glutamate-induced injury, and restored glutamine synthesis and glutamate transporter 
expression in astrocytes under inflammatory insult. The in vitro efficacy translated into in 
vivo efficacy, as treatment initiated after disease onset reduced the clinical progression of 
chronic EAE in mice, suggesting this may be useful in the treatment of progressive MS 
and other neurodegenerative diseases.  
A fullerene-based MS therapeutic was designed to specifically target axonal cells. 
Here a MC-stabilizing FD was conjugated with tropine and an IR800 dye for tracking 
[22]. This MC-stabilizing compound is targeted to neurons based on the affinity of 
tropine (a derivative of tropane containing an oxygen atom) for neuronal cell dopamine 
transporter receptors [57]. Thus, in addition to its ability to inhibit MC-mediator release, 
this compound is theorized to also target neurons and scavenge ROS. To determine if this 
MC-stabilizing, neuron-targeting, IR800 dye fullerene molecule could cross the BBB, 
mice were injected intravenously with fullerene dye, and imaged immediately and at 
several time points.  
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Initial experiments show the fullereneWdye conjugate can cross the BBB and be 
deposited in the brain (Figure 2.6). This approach using basic chemistry to add a variety 
of axon/neuron-targeting motifs with varying ratios of targeting motif to the fullerene 
core is now being used to foster maximal cell targeting and uptake. These results confirm 
previous studies using a C60-based formulation suggesting FDs can cross the BBB. First, 
mice orally treated with FDs have reduced superoxide generation in the brain [58]. 
Second, FDs given orally can reverse age-related changes in mitochondrial electron trans-
port function and block age-related increases in superoxide produced by mitochondria 
taken from the brain [17, 59]. 
  
 
Figure 2.6.  A Neuron-Targeting Fullerene Crosses the Blood!Brain Barrier. Mice 1 
and 2 were injected with 0.5 ml of the IR800 dye-labeled fullerene by tail vein 15 
min apart. Mouse 3 is a control (no dye). The brain was removed at 6 h, sectioned 
and scanned. 
 
The SH-SY5Y human neuroblastoma cells express dopamine transporters and 
were differentiated into nondividing neurons using a protocol described previously [60]. 
A Texas Red® (Life Technologies, CA, USA)-conjugated, fullereneWtropane derivative 
clearly recognized the neuronal dopamine transporter receptors (Figure 2.7A). This is 
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evident by the accumulation of clusters of red (from the Texas Red dye) on the 
membrane of the neurons and also staining of the neuronal axon. Interestingly, it appears 
there is an abundance of fullereneWtropane at the newly formed part of the axon (closest 
to the cell core) but not towards the outer axon sheath. FullereneWtropane also penetrates 
into cells where there is evidence of mitochondrial colocalization (Figure 2.7B).  
          
 
Figure 2.7.  Fullerene!Tropane Derivatives can Target the Neuronal Dopamine 
Transporter Receptors on Human Neuroblastoma Cells. A neuron-targeting 
fullerene derivative (A) colocalizes with mitochondria and (B) selectively binds 
neuronal cells through tropane receptors. 
 
MCs are important regulators of MS [54-56]. Oxidative stress, through the 
generation of ROS, is an underlying mechanism that mediates MC signaling and MS 
pathology [61]. Indeed, several antioxidants are currently in various phases of human 
clinical trials (i.e., lipoic acid, inosine and Triomar® [Pronova Biocare, Oslo, Norway], 
see [62]). Given that FDs can stabilize MCs [22], are potent antioxidants [49, 63] and are 
anti-inflammatory medications [15, 48], FDs were tested for their ability to inhibit EAE. 
As seen in Figure 2.8, FDs reduce the clinical scores associated with MS in the EAE 
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model, suggesting this class of rationally designed compounds may be used as a platform 
for new areas of therapeutic research for MS. 
 
        
Figure 2.8.  Fullerene Derivatives Inhibit the Onset of Experimental Allergic 
Encephalomyelitis. Fullerene derivatives inhibit the onset of experimental allergic 
encephalomyelitis in mice assessed at day 6 (triangles) and day 10 (squares) 
compared with nontreated animals (circles). 
 
II.7 Fullerenes as Diagnostics 
Carriers for diagnostics have shown great potential in solving many present day 
medical imaging limitations. Endohedral fullerenes consist of a hollow core carbon shell, 
which during synthesis is capable of encapsulating metal ions within the cage. The 
endohedral fullerene cage is typically larger than the common C60. This is due to size 
constraints imposed by the small size of the C60 molecule; therefore, C80 molecules (or 
even higher: C82, C84, C86, C88 and C2n; i.e., n = 12, 13, 14 and so on) accommodate 
sufficient enclosure of desired metals, including lanthanum, yttrium, scandium and 
+,C/$)*)(D0#8B%#%*C/B%C?,$#A($$%?%*%F'#'.?/*+#%$%-.?/*)-#E?/Eerties can strongly enhance 
diagnostics. Such compounds are currently being investigated as a platform to detect 
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cancer [64], atherosclerosis [65] and arthritis [66]. Present day diagnostic limitations of 
both sensitivity and specificity have stalled progress on accurate, enhanced patient 
imaging. Thus, metal endohedral fullerenes have the potential to affect the diagnosis of 
numerous other diagnostic pathologies.  
One class of endohedral fullerene is typified by Trimetaspheres® (TMS; Luna 
Innovations Incorporated, VA, USA), which are C80 based with gadolinium enclosed 
within the cage (Figure 1.1C). One field in which they are being investigated for use is in 
MRI W a widely used diagnostic procedure that utilizes gadolinium-based contrast agents 
2)0%0G#9,+*%&)'.XY#",>%?#M%,$.BS,?%#ZB,?D,-%(.)-,$'#=*-0G#[\G#]4^60#M/R%&%?G#'%&%?,$#
issues have limited gadolinium chelate-based contrast agents (i.e., Magnevist) for use as 
image-guided interventions with MRI, including gadolinium toxicity [67-70], rapid 
clearance from the body, poor relaxivity-dependent sensitivity and inability to be targeted 
to disease-specific biomarkers. The TMSs solve many of the problems associated with 
current gadolinium-based contrast agents. First, the gadolinium (inside cage) that is toxic 
at sufficient concentrations is separated from active targeting moieties (outside cage) by 
an extremely stable carbon shell, possibly increasing safety. Unlike current chelates, 
adding targeting ligands/moieties to TMSs does not affect the ability of gadolinium to 
become free of the compound. Second, gadolinium-encapsulated endohedral fullerenes 
are more sensitive. Targeted imaging agents require strong signals by which to report the 
presence of an agent at a particular location. The TMS achieves 25- to 50-fold greater 
relaxivity compared with traditional gadolinium contrast agents. Third, the fullerene cage 
can be targeted to disease biomarkers, as targeting moieties can be attached to the cage 
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(including empty cage fullerenes). Finally, the TMSs appear to be safe; no toxicity was 
detected in vitro and in vivo [49, 71], although further studies to assess their safety are 
clearly needed.  
The crux of the TMS platform for diagnosis utilizes specific biomarkers 
conjugated to the gadolinium-encapsulated endohedral fullerene MRI contrast agents and, 
in theory, could be used for any disease for which specific expression of suitable 
receptors exist. Two disease processes evaluated, atherosclerosis and glioblastoma, 
possess disease-specific biomarkers that can be targeted. Based on working prototypes, 
TMS endohedral fullerenes have been developed to study their cellular uptake by 
macrophage foam cells (for atherosclerosis) and glioblastoma cells (for cancer) in vitro. 
This prototype takes advantage of already identified biomarkers on diseased cells, 
followed by chemically attaching ligands to target the TMS to these cells (characterizing 
the molecules), and use of in vitro assays to determine if they bind to and enter the cells 
and assess any toxicological effects. 
II.8 Endo-Fullerene Contrast Agents as Diagnostics for Atherosclerotic Plaque 
Atherosclerosis is an inflammatory disease representing a major healthcare 
problem in the USA. Initiation of atherosclerosis begins when blood cells (monocytes) 
I'.)-TF#./#H$//C#&%''%$#R,$$'#,'#,#?%'($.#/A#,*#)*C)&)C(,$F'#)*-?%,'%C#-B/$%'.%?/$#
consumption. Over time the cells continue to accumulate on vessel walls and engulf the 
fat droplets until large structures called plaques begin to form. The plaque can rupture 
and lead to complete blockage of blood flow through the vessels involved, leading to a 
 
!
23 
heart attack and/or stroke. To be able to noninvasively determine the extent of plaque 
build up in vessel walls of at risk patients using already established diagnostic procedures 
would facilitate treatment options that could greatly reduce myocardial infarction and 
stroke incidence, which represent the most frequent causes of death in western society.  
While several molecules have already been identified that are selectively expressed or 
highly upregulated on plaque lesions [72-74], preliminary findings in the field focus on 
CD36 (macrophage scavenger receptor) as a potential target receptor. The CD36 receptor 
is involved in foam cell formation, mediating the influx of lipids into macrophages, 
possessing a promiscuous ligand binding and is highly expressed on lipid-laden 
macrophages of human atherosclerotic aorta [75-78]. Different forms of oxidized 
phosphatidylcholine and oxidized low-density lipoprotein are high affinity ligands for 
CD36 [79]. The basic structure of the compounds consists of the TMS enclosed within 
liposomes, which was previously demonstrated [48], with CD36 ligands decorated on the 
liposomes (Figure 2.9). As seen in Figure 2.10, APOE knockout mice [80] were used to 
test the atherosclerotic plaque-targeting contrast agent, which serves as a working 
prototype for a new class of diagnostic agents that specifically attach to atherosclerotic 
plaques, so that previously undetected lesions can be diagnosed using MRI. The 
atherosclerotic plaque-targeting contrast agent clearly reveals plaque accumulation by 
MRI that is not seen using the same molecule without targeting ligands. 
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Figure 2.9.  Basic Structure of Atherosclerosis-Targeting Contrast Agents. Not 
drawn to scale. Gd-TMS: Gadolinium Trimetaspheres®; PC: Phosphatidylcholine. 
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Figure 2.10.  Atherosclerotic Plaque-Targeting Contrast Agents can Detect Plaque 
In Vivo. ApoE-/- with plaque were imaged using MRI. The (A) ATCA or (B) 
nontargeted controls were injected intravenously and images of the descending 
aorta acquired before or 120 min after. The arrow indicates the ATCA binding to 
the plaque in the blood vessel, while the controls do not. ATCA: Atherosclerotic 
plaque-targeting contrast agent. 
 
II.9 Fullerenes as Theranostics 
Multifunctional approaches that incorporate both medical imaging and therapy 
could be the future of medicine, and fullerenes prove to be an attractive platform for these 
,EE?/,-B%'0#8B)'#)'#C(%#./#.B%#A($$%?%*%F'#,H)$).>#./#')D($.,neously detect (with 
biomarkers), image (with gadolinium-based contrast) and deliver a therapeutic payload to 
a specified site. Progression can be monitored in real time to assess the effectiveness of 
treatment using direct visualization of the areas of interest through the high-contrast 
capabilities of endohedral fullerenes. Nanoparticles are presently being pursued for imag-
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ing and diagnostic applications [81, 82] and the next logical leap would be to couple this 
with patient therapy. Such multifunctional nanoplatform-based probes have shown to be 
effective in mouse models, including tumor detection and treatment [83-85], as well as 
atherosclerosis and arthritis [86-88]. 
II.10 Endo-Fullerene Contrast Agents as Theranostics for Brain Cancer 
Glioblastoma multiforme is an aggressive high-grade brain tumor with a poor 
prognosis. Ideally, a multifunctional nanoscale compound is needed that can 
simultaneously diagnose tumor progression and can also specifically target and kill the 
tumor. IL-13 receptors are selectively expressed on astrocytoma cells in gliomas. It has 
been previously reported that IL-13 receptor-targeted chemotherapies (diphtheria toxin) 
[89, 90] delivered through lipid nanovesicles (liposomes) were effective in targeting and 
shrinking glioma tumors in a subcutaneous tumor model. MRI using gadolinium-based 
contrast agents has been used for diagnosing glioblastoma. IL-13 receptors are expressed 
on glioblastoma multiforme cells and are not significantly expressed in normal tissue 
[91]. In fact, many clinical trials are underway using IL-13 as a targeting moiety for 
various interventions of the disease [62]. TMS was used as a platform for developing 
novel glioblastoma-targeting theranostics in which the diagnostic TMS is enclosed within 
glioblastoma-targeting IL-13 liposomes that can deliver a therapeutic payload of 
doxorubicin (Figure 2.11).  
After verifying in vitro binding of the glioblastoma-targeting theranostics to 
human glioblastoma cells, the nanoparticles were tested in vivo. As seen in Figure 2.12, 
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the glioblastoma theranostic can target and shrink human brain tumors that have been 
transplanted in mice. 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Glioblastoma-Targeting Theranostic. The Trimetaspheres® (Luna 
nanoWorks, VA, USA) are incorporated within and/or in the liposome bilayer along 
with doxorubicin and are targeted to the glioma cells by IL-13 (not drawn to scale). 
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Figure 2.12.  Glioblastoma-Targeting Nanovesicles with a Therapeutic Payload 
Attached can Shrink Brain Tumors. Mice with human glioblastoma cells injected 
into the brain have uncontrolled growth (white mass). (A) When mice are injected 
with targeted nanovesicles the tumors shrink and disappear over time (as 
determined by MRI). (B) However, tumor size increases significantly over time in 
mice injected with nontargeted nanovesicles. GTTN: Glioblastoma-targeting 
theranostics. 
 
II.11 Fullerene Toxicity 
Of course, toxicity considerations are implicit when contemplating human use for 
novel compounds such as fullerenes. To this end there have been a number of studies 
examining the toxicity using a myriad of fullerene preparations. However, the results of 
most of these studies are conflicting, inconclusive and the subject of much debate. One 
such fullerene study (which was subsequently proven to be unfounded) exposed juvenile 
bass to nonderivatized C60, which is insoluble in water [92]. Unfortunately the authors 
did not include a control that provided insights into whether the observed effects were 
simply due to large aggregated particles, tetrahydrofuran contaminants or whether they 
were specific to the chemical nature of C60. However, there was widespread publicity that 
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concluded fullerenes as a class of compounds could be toxic [93]. A subsequent 
publication by the same group (without publicity) demonstrated that the originally 
/H'%?&%C#I./K)-).>F#R,'#C(%#./#)DE(?).)%'#)*#.B%#',DE$%#[94]. Even more recently these 
original studies were formally addressed by a follow-up publication, which stated that the 
/?)+)*,$#LH%?C/?'.%?#'.(C>#R,'#I-/DE?/D)'%C#H>#%KE%?)D%*.,$#,?.)A,-.'F#[95]. On the 
opposite end of the spectrum, studies in mice demonstrate that similar C60 preparations 
significantly increase the lifespan of mice [17] and rats [18]. Thus, it is difficult for 
researchers, and the general public, to determine if fullerenes are dangerous 
nanostructures that should be banned or a potential novel platform for developing new 
medicines. The answer to explain how a class of compounds can be simultaneously toxic 
and lifespan extenders will rely on well-controlled structureWactivity studies.  
Contributing to the confusion is that few studies examining toxicity use well 
characterized and highly purified material; those that are not mixtures of many isomers, 
aggregate sizes and impurities. Most studies in which fullerenes are deemed to be toxic 
use starting material with little or no characterization (e.g., dynamic light scattering, z-
potential and Fourier transform infrared spectroscopy). In addition, no studies have 
compared differences in cage sizes (C60 vs C70 vs C80); the latter two are much more 
likely to become US FDA-approved products owing to their size being conducive to 
fewer numbers of isomers when adding side-chain moieties. The FDA requires that every 
new chemical entity must be evaluated separately; extrapolating toxicity (or nontoxicity) 
by categorizing compound mixtures and making generalizations about classes of 
compounds (as is the case with fullerenes) with many different isomers is not acceptable 
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to the FDA. A fundamental understanding of basic chemistry reveals that even extremely 
similar molecules can have different biologic activities. There are many examples where 
two isomers that are very similar have completely different biological behavior. For 
example, the tragedy of the drug thalidomide, where one isoform was an effective 
sedative and the mirror image isoform was teratogenic (resulting in fetal defects), 
changed the face of drug testing. It is important to note that pristine nonfunctionalized 
fullerenes behave significantly differently to their water-soluble functionalized 
counterparts, furthermore each variation in fullerene functionalization should be treated 
and evaluated as a separate entity. This applies to the studies with fullerenes, where even 
extremely small changes in the core fullerene structure (through the addition of side-
chain moieties) can result in the FD having completely different biological properties. 
Several laboratories have demonstrated this repeatedly, which highlights the difficulty in 
interpreting data gathered from extrapolating findings between even very similar 
compounds.  
Complicating the task of bringing FDs to the marketplace is the fact that the FDA 
does not have specific guidelines for products containing nanoscale materials. A report 
issued by the FDA Nanotechnology Task Force (July 2007) recommends guidance by 
various centers within the FDA for industries working with nanomaterials [96]. Unlike 
I'.,*C,?CF#C?(+#E?/C(-.'G#).#)'#)*-?%,')*+$>#%&)C%*.#.B,.#,.#$%,'.#)*#.B%#,?%,#/A#
characterization of nanomaterials used in drug products different standards apply. 
Applying small molecule principles and methodologies to nanomaterials cannot be 
extrapolated in biological settings. The study stressed that biodistribution analysis should 
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be at the core of any evaluation of products containing nanomaterials. These 
biodistribution studies, as recommended by the FDA [96], provide valuable information 
on where the nanoparticles are traveling and possibly accumulating, therefore, subjecting 
those sites to increased likelihood of toxicological effects. It was also stressed in the 2007 
report that most studies (using nanomaterials) are limited in that they are short-term and 
might leave long-term effects unevaluated, especially because the long-term toxicity and 
effects for most nanoscale materials remain unknown. Furthermore, appropriate end 
points for in vitro assays are seen to be difficult to determine, as single cell types are 
often not sufficient for evaluation on the function or health of organs or tissues that are 
made up of multiple cell types, given that FDs are exposed to numerous types of tissues 
in the body. The major recommendation from the reports was that nanoscale materials be 
characterized with respect to size (surface area and size distribution), chemical 
composition (i.e., purity and crystallinity), surface structure (e.g., surface reactivity, 
surface groups and coatings), solubility, shape and aggregation. The protocols developed 
at the National Cancer Ins.).(.%F'G#[,*/.%-B*/$ogy Characterization Laboratories (MD, 
USA) was recommended as being very useful in helping to characterize nanoscale 
materials, and to develop standards and standardized methods for measuring nanoscale 
materials [97].  
At present, it is difficult to make conclusions on the absorption, distribution, 
metabolism and excretion profile of the many types of carbon nanomaterials presently 
being investigated: carbon nanotubes; nanohorns; graphene; fullerenes; and derivatives of 
each of these nanomaterials. This is primarily due to the relative infancy of the field and 
 
!
32 
limited research on the long-term effects of fullerenes on biological systems. However, 
several studies have been conducted assessing the elimination of fullerenes from the body 
[19, 98]. Researchers have concluded that there is limited absorption of fullerenes fol-
lowing both intravenous and oral exposure in rats. In general, elimination was rapid from 
the body via feces and urine [19, 98]. Furthermore, several experimental studies revealed 
that mice treated with excessive dosages (2000 mg/kg) of fullerenes have shown no overt 
toxicity [99, 100]. In fact, some studies have shown that fullerene treatment in mice and 
rats can improve cognitive function and extend lifespan by 11% (in the mouse model) 
and 90% (in the rat model) [17, 18]. Clearly contrasting results and limited long-term 
data need to be addressed and efforts on creating reliable, reproducible results are still 
required for successful translation of these molecules into human systems. Focusing 
research to clarify chronic exposure to these materials, as well as identification of 
genotoxicity, carcinogenicity and reproductive toxicity will be paramount for 
encouraging fullerene studies in biological systems. Certainly, each carbon nanomaterial 
and specific derivatives should be carefully evaluated and characterized individually, as 
these materials exist in a variety of forms (e.g., carbon structure, carbon number, surface 
modification, charge, size, aggregation and degree of functionality). The extrapolation of 
results across such broad classes is not sufficient in characterizing the toxicity profiles of 
these molecules.  
Future research should be aimed at devising appropriate testing strategies to 
evaluate risk and toxicity profiles that do not generalize carbon nanoparticles as one, but 
rather evaluate each class individually. 
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CHAPTER III 
FULLERENES INHIBIT ALLERGIC MEDIATOR RELEASE FROM HUMAN MAST 
CELLS AND BASOPHILS 
 
 
III.1 Introduction 
Mast cells (MC) are ubiquitously expressed in almost all tissue and participate as 
effector cells for immune regulation. Peripheral blood basophils (PBB) are similar to MC 
in that they have pre-stored, allergy inducing mediators in their granules (e.g. histamine). 
Once stimulated, MC/PBB secretes several molecules, including preformed and newly 
formed inflammatory mediators, via various physiological and nonphysiological 
stimulations [30, 101, 102]0#_B)$%#.B%#-$,'')-,$#=+@`7-;<=#E,.BR,>#)'#.B%#D/'.#R%$$#
studied and understood pathway leading to MC/PBB mediator release, these cells can be 
stimulated by non-IgE secretagogues. 
Indeed, non-IgE stimulation may be more physiologically relevant in non-allergic 
conditions such as innate immunity and heart disease [30, 63, 103]. Thus, finding new 
ways to stabilize these cells as a strategy for controlling MC/PBB-diseases is a 
continuous need. Fullerenes, which are nanometer-sized tiny spherical carbon cages, are 
being explored in a wide array of applications including nanomedicine [63, 104]. The 
carbon cage is insoluble without the addition of appropriate side chains that confer water 
solubility, an important requirement for medical applications. Recent studies suggest that 
water-'/$(H$%#A($$%?%*%#C%?)&,.)&%'#2756#-,*#)*B)H).#7-;<=-induced MC responses in 
vitro, which translates to the prevention of MC-driven anaphylaxis and asthma in vivo 
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[20, 22, 32]. Although it is clear certai*#75#-,*#'.,H)$)a%#9S#,-.)&,.)/*#.B?/(+B#7-;<=#in 
vitro and in vivo it is not known if they can stabilize MC activation through non-7-;<=-
mediated stimuli. In these studies, the non-7-;<=`=+@#D%C),.%C#)*B)H)./?>#%AA%-.'#/A#,#
panel of FD were tested for their ability to stabilize MC/PBB. It is shown that incubation 
of MC/PBB with fullerene constructs can significantly inhibit mediator release in 
response to various secretagogues. This inhibition was mediated in part through 
reductions in the generation of reactive oxygen species (ROS), cellular fluctuations of 
calcium, and phosphorylation of signaling molecules in activated MC. It is demonstrated 
that FD inhibit non-IgE mediated pathways and the efficacy of FD relies on several 
factors: the active side chain moieties added to the fullerene cage, the type of cells 
evaluated, the secretagogue used to stimulate, and the pathway that is examined. 
III.2 Methods 
III.2.1 Fullerene derivatives 
Luna Innovations Incorporated synthesized all FD. Each FD was characterized 
using matrix assisted laser desorption ionization mass spectrometry (MALDI-TOF), 
nuclear magnetic resonance (NMR), and high performance liquid chromatography 
(HPLC). All FD used were between 1 and 50 nm in aqueous solution as determined by 
dynamic light scattering (DLS) using a Malvern Zetasizer Nano-S90 and a NanoSight 
LM10 with NTA Software allowing individual particles to be tracked and characterized. 
To evaluate fullerene-specific toxicity, MC viability was determined by incubation with 
concentrations (E#./#bcc#d+`D$#/&%?#*)*%#C,>'#2,#bcK#B)+B%?#-/*-%*.?,.)/*#,*C#$/*+%?#
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time period than was needed to control cellular responses to stimuli). No significant 
(p<0.05) toxicity was observed with any of the selected compounds when compared to 
controls as determined using trypan blue staining and MTT Assay. 
III.2.2 Human mast cell and peripheral blood basophil cultures and activation 
Human tissue (i.e. skin) was received from the Cooperative Human Tissue 
Network. All MC studies were approved by their Human Studies Institutional Review 
Board. Mast cells were purified and cultured as described [105, 106]. Peripheral blood 
basophils were obtained from normal donors (no medications) after informed consent as 
approved by the Institutional Review Board, Johns Hopkins University and purified to 
>90% as described previously [107]. 
A panel of FD was screened at several concentrations to determine their ability to 
inhibit secretion. Briefly, MC/PBB were first incubated with increasing concentrations of 
FD (1-ec#d+`D$6#/&%?*)+B.#2bf#B) at 37°C and 6% CO2, a time point and concentration 
range found to be optimal for cellular uptake of FD [21, 22]. The next day, cells were 
stimulated with the indicated secretagogues at varied concentrations for 30 min 
(degranulation and PGD2) or overnight (cytokine production) at 37°C and mediator 
release measured as described previously or according to the manufactures instructions 
(Cayman Chemical Company, Ann Arbor, MI, Prostaglandin D2 Kit-512031). The 
percent inhibition was calculated as a percent release compared to non-FD treated cells 
(positive control). An initial dose response was performed to determine the concentration 
of secretagogues that induced maximal degranulation/cytokine production (not shown).  
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=*#'B/?.G#9S#?%'E/*C%C#/E.)D,$$>#./#bc#d9#R).B#^OPbfg#,*C#-/DE/(*C#ef`fcG#
Oc#d9#A/?#'/D,./'.,.)*G#,*C#ec#d9#A/?#E/$>#h-lysine. Other secretagogues (C5a, 
morphine, substance P, and LPS) were examined, however preincubation with FD did not 
produce statistically significant reductions in MC mediator release or stimuli did not 
induce significant activation (data not shown). For P""G#bc#d9#R,'#/E.)D,$#,-.)&,.)/*#
with fMLP, poly L-lysine, and A23187 (data not shown). All studies were performed in 
triplicate on at least three separate MC cultures or PBB donors. 
III.2.3 Reactive oxygen species and calcium measurements 
Human skin MC (2x106/ml) were incubated overnight with FD (those found to 
significantly inhibit degranulation and/or cytokine release), washed, and loaded with 
DCF-DA (final concentration of 5 d96#A/?#Pc#D)*. Following fluorophore loading, cells 
were washed and resuspended in fresh media, placed in a cuvette, and activated with 
various secretagogues (as above) for ~60 s. ROS fluorescence intensity was measured at 
523 nm wavelengths over a 12-minute time interval using Perkin Elmer LS55 
Luminescent Spectrometer (Perkin-Elmer Laboratories). For calcium flux, MC 
(incubated as above) was loaded with Fura-2 AM at a final concentration of 20 ng/ml for 
30 min at 37°C in HBSS buffer. The cells were washed twice in the same buffer and 
incubated for 15 min. The cells were then stimulated with appropriate secretagogues and 
a real time ratiometric intensity evaluation of fluorescence between wavelengths 340 
nm/380 nm was determined over a period of 400 s using Perkin Elmer LS55 Luminescent 
Spectrometer. All samples were measured in duplicate and performed at least three times. 
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III.2.4 Immunoblotting analysis of signal transduction intermediates 
Mast cells (1x107 cell/condition; each condition performed in triplicate) were 
prepared for Western blotting as described previously [22]. Briefly, cells were incubated 
with or without optimal concentrations of the indicated FD overnight, washed, and 
activated as described above. Cell pellets were lysed and nuclear extracts isolated as 
described [108]. The cell suspension was heated, passed through a 20-gauge needle, and 
centrifuged to remove cell debris. Proteins were separated on 12% NuPage tris-glycine 
gels using tris-glycine SDS running buffer. Signaling molecules were measured using 
phosphorylated MAPK (ERK1 and ERK2) and LAT primary antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA or Cell Signaling, Danvers, MA, respectively) and Licor 
IR-800 anti-D/('%#7#2,H6O#'%-/*C,?>#,*.)H/C)%'#2biOcGccc60#8B%#B/('%T%%E)*+#E?/.%)*#j-
actin was used as a loading control on the same blot and co-stained with Licor IR-600 
anti-rabbit F (ab)2 secondary antibodies. Band intensities were quantified using an 
Odyssey Imaging System as previous described [22]. 
III.3 Results 
III.3.1 Fullerenes differentially effect mast cell non-IgE-induced mediator release 
A panel of water soluble FD was evaluated to determine efficacy based on various 
side chain moieties as well as differential responses to numerous secretagogues. Table 3.1 
presents results from a subset (~30%) of FD that was capable of significantly (p<0.05) 
inhibiting MC-degranulation when challenged with 48/80, somatostatin, A23187, and 
poly-L-lysine. Other secretagogues evaluated included C5a, morphine, substance P, and 
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LPS which did not produce significant mediator release from MC or the pathway was 
unaffected by FD pretreatment, data not shown. These data demonstrate that inhibition of 
non-IgE-driven MC-degranulation can be generalized across various stimuli, as in the 
case of C70-OH and Tetrasulfonate, or selective to a specific stimuli and/or signaling 
pathway, as observed in the case of Biotin and CCC. 
 
Table 3.1. Mean % Inhibition of Degranulation (±SD) in FD Treated and Untreated 
MC. 
 
 
* FD Treatment at bc#d+`Dh0 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed 
 
Table 3.2 represents those FD that were effective at significantly inhibiting TNF-
1#->./T)*%#E?/C(-.)/*#A?/D#9S0#L(.#/A#A)&%#'%E,?,.%#9S#-($.(res, no activation of 
cytokine production was observed with compound 48/80 or somatostatin (varying dose 
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,*C#)*-(H,.)/*#.)D%'Y#E/').)&%#-/*.?/$'#(')*+#7-;<=#,*.)H/C)%'6#,'#/.B%?'#B,&%#?%E/?.%C#
[109]. 
 
Table 3.2. Mean % Inhibition of TNF-"#$%&'(#)*#+'#,-./0.1#/*1#2ntreated MC. 
 
k75#8?%,.D%*.#,.#bc#d+`Dh# 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed 
 
Calcium ionophore (A23187) is a widely used secretagogue which can directly 
increase intracellular calcium concentration (calcium) levels to induce mediator release 
[110]. Nine FD significantly (p<0.05) inhibited degranulation (>10%) (Table 3.1). 
Furthermore, 13 FD were capable of inhibiting TNF-1#->./T)*%#E?/C(-.)/*#2lec:6#
induced by A23187 (Table 3.2). Poly-L-lysine is a small polypeptide of the essential 
amino acid L-lysine that can induce MC activation [111, 112]. Seven of the FD inhibited 
degranulation (>10%) and six were capable of inhibiting TNF-1#E?/C(-.)/*#28,H$%#3.1 
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and 3.2). Typical dose response curves of inhibition on degranulation and cytokine 
production are indicated in Figure 3.1A-D. 
 
 
Figure 3.1.  Specific FD Inhibit Human MC Calcium-Ionophore and Poly-L-Lysine-
Induced Mediator Release in a Dose Dependent Manner. Mast cells were incubated 
overnight with FD, washed and activated with increasing concentrations of A23187 
(A and B) or poly-L-lysine (C and D) for 30 min (degranulation, A and C) or 18 h 
(cytokine, B and D). Mediator release was assessed as described in materials and 
methods. Figures are representative of three separate MC cultures with each 
condition performed in triplicate. 
 
 
Compound 48/80 is a polybasic secretagogue, which has previously been shown 
to activate human MC [113, 114] presumably through direct interactions with guanosine 
triphosphate (GTP)-binding proteins and MAPK [115]. As seen in Table 3.1, five FD 
inhibited degranulation in MC challenged with compound 48/80 (>20%). Somatostatin is 
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a peptide hormone that has previously been shown to activate human MC [114, 116] 
through the G-protein-coupled somatostatin receptor [114, 117]. Table 3.1 shows a subset 
of 11 different FD that inhibited degranulation. A representative dose response for 
inhibition is seen in Figure 3.2A and B. 
 
 
Figure 3.2. Specific FD Inhibit Human MC Compound 48/80- and Somatostatin-
Induced Degranulation in a Dose Dependent Manner. Mast cells were incubated 
overnight with FD, washed and activated with increasing concentrations of 
compound 48/80 (A) or somatostatin (B). Mediator release was assessed as described 
in materials and methods. Figures are representative of three separate MC cultures 
with each condition performed in triplicate. 
 
 
III.3.2 The effect of FD on non-IgE induced mast cell PGD2 release 
 
The panel of FD (Tables 3.1 and 3.2) evaluated for mediator release were 
investigated to determine if they could reduce PGD2 production in MC. TGA, Niacin, 
Biotin, and Tetrainositol were selected based on to their ability to inhibit cytokine 
production and degranulation in activated MC in response to a number of stimuli. Neither 
Biotin nor Tetrainositol resulted in any inhibition of PGD2 production. Mast cells 
preincubated with TGA or Niacin and challenged with A23187, 48/80, or poly-Llysine 
decreased PGD2 production by >60% in all conditions, (Table 3.3). No detectable levels 
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of PGD2 where observed in MC-activated with somatostatin. Additionally, PGD2 
production in IgE challenged (Fc!RI) MC was reduced by nearly 60% by FD 
pretreatment. 
 
Table 3.3. Mean % Inhibition of PGD2 Production (±SD) in FD Treated and 
Untreated MC. 
 
 
* FD Treatment at 10 µg/mL. 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed / ND = none detected 
 
III.3.3 The effect of FD on non-IgE induced peripheral blood basophil mediator release 
The secretagogues that induce mediator release from PBB are different from those 
that induce mediator release from MC [118]. The effects of FD on N-formyl-methionine-
leucine-phenylalanine (fMLP) and poly-L-lysine-induced mediator release from PBB are 
shown in Table 3.4. Only Ethanolamine inhibited fMLP-induced degranulation (14%). 
Tetrainositol, TGA, and Niacin inhibited IL-13 release when activated with fMLP, but 
none significantly affected poly-L-lysine induced mediator release as seen in Table 3.5. 
None of the FD evaluated inhibited A23187-induced PBB degranulation (data not 
shown). 
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Table 3.4. Mean % Inhibition of Degranulation (±SD) in FD Treated and Untreated 
PBB. 
 
 
* FD Treatment at 10 µg/mL. 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05  
no Inh = no significant inhibition observed / ND = none detected 
 
 
Table 3.5. Mean % Inhibition of IL-13 (±SD) in FD Treated and Untreated PBB. 
 
      
* FD Treatment at 10 µg/mL. 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed 
 
 
III.3.4 The effect of FD on non-IgE mediated induced ROS activity and intracellular 
calcium flux in mast cell 
We next began to delineate the mechanisms of inhibition focusing on MC given 
the difficulty in obtaining adequate numbers of PBB for such studies. The activation of 
MC and subsequent degranulation is calcium-dependent and results in elevated ROS 
levels [119]. It was hypothesized that FD reduced MC degranulation by blocking ROS 
production and calcium responses. Therefore, representative FD was selected based on 
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their ability to inhibit A23187, compound 48/80, somatostatin, and poly L-lysine-induced 
degranulation.  
A23187-induced increases in ROS and calcium fluctuations were significantly 
reduced by TGA (~50% for ROS, ~70% for calcium) and Ethanolamine (~50% for ROS, 
~90% for calcium) (Figures 3.3A and 3.4A). Niacin and Tetrasulfonate significantly 
reduced compound 48/80-induced ROS activity (>30%; Figure 3.3B), but selectively 
effected calcium levels (Niacin > 80% inhibition and Tetrasulfonate was ineffective; 
Figure 3.4B). Somatostatin stimulated MC pretreated with Biotin and TTA inhibited ROS 
and calcium activity by approximately 30% (ROS) and 75% (calcium) (Figures 3.3C & 
3.4C). Lastly, Figures 3.3D and 3.4D demonstrate TGA and TTA blunted ROS 
generation >50% in response to poly-Llysine as well as inhibited calcium approximately 
30% compared to the positive control. Thus, FD appears to inhibit mediator release 
through the blunting of secretagogue-induced cellular increases in ROS and intracellular 
calcium stores. 
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Figure 3.3. Fullerene Derivatives Inhibit Secretagogue-Induced Elevations in 
Intracellular ROS Levels. Mast cells were incubated overnight with FD, washed and 
DCF-DA added to cells for 30 min at 37
o
C. After washing cells were activated with 
optimal concentrations of the indicated secretagogue and the fluorescence intensity 
measured at 525 nm after establishing baseline. Figures show duplicate samples for 
each condition and are representative of three separate MC cultures. All positive 
controls (activated but not pre-incubated with FD) were represented by red traces 
and all negative controls (non-activated and non-preincubated with FD) are denoted 
by black traces. 
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Figure 3.4. Fullerene Derivatives Inhibit Secretagogue-Induced Elevations in 
Intracellular Calcium Levels. Mast cells were incubated overnight with FD, washed 
and FURA 2 added to MC and incubated for 20 min at 37
o
C in the dark. After 
washing cells were activated with optimal concentrations of the indicated 
secretagogue and intensity of fluorescence was read as a ratio 340 nm and 380 nm 
wavelengths. Figures show duplicate samples for each condition and are 
representative of three separate MC cultures. 
 
III.3.5 The effect of FD on non-IgE mediated signaling pathway intermediates 
To further delineate the mechanism of action of the FD on non-IgE-mediated 
degranulation we examined Western blotting using antibodies to the phosphorylation-
dependent activated forms of LAT and ERK1/ERK2 [120, 121]. As seen in Figure 3.5A 
neither Biotin or TTA significantly affected A23187-induced changes in MAPK or LAT. 
Niacin and Tetrasulfatonate both reduced compound 48/80-induced phospho-activation 
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of MAPK and LAT (Figure 3.5B) while Biotin and TTA both reduced somatostatin-
induced changes (Figure 3.5C). Both TGA and TTA reduced poly-L-lysine induced 
activation of MAPK with minimal effects on LAT. No changes in the phosphorylation 
state of other signaling pathways examined including the Src family of kinases and 
phosphoinositol 3-kinase (PI3K) pathway were observed under these conditions (data not 
shown). 
 
 
Figure 3.5. Inhibition of Mediator Release in Calcium Ionophore, Compound 48/80, 
Poly-L-Lysine, and Somatostatin Challenged MC Involves the Down-Regulation of 
MAPK and LAT Phosphorylation. MC were incubated with or without the FD 
overnight, washed and activated with the indicated secretagogue. Western blotting 
was performed as described previously in Methods with the indicated Abs and 
Odyssey IR800-anti-rabbit secondary antibodies. In both cases, the total protein 
content in lysates was measured with the house keeping gene 3-Actin and Odyssey 
IR680-anti-mouse secondary antibody. 
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III.4 Conclusions 
Mast cells and PBB contribute to several disease processes through the release of 
inflammatory mediators through both IgE and non-IgE mechanisms. Thus, therapies 
aimed at stabilizing them and preventing the release of their mediators has been the 
subject of research for many years. For example, omalizumab, the humanized IgE 
specific IgG1 monoclonal antibody, which limits the amount of free IgE available to bind 
7-;<=#/* the surface of MC/PBB, can control severe allergic asthma [122, 123]. Another 
MC stabilizer, Cromolyn, has been effectively used to treat a wide range of MC-driven 
diseases [124-126]. The significance of these studies is that FD has a broad range of 
inhibitory capabilities toward inflammatory cells and has not demonstrated acute toxicity 
in vitro. Since MC/PBB can be induced to secrete their inflammatory mediators through 
several non-overlapping pathways these molecules represent a new strategy for 
therapeutics aimed at those disease mediated by these cells such as allergy, asthma, and 
arthritis. 
As in our previous studies examining IgE-7-;<=-mediated degranulation and 
cytokine production [20, 22], the efficacy in of FD was strongly dependent upon specific 
side chains additions; approximately 20% of the FD tested exhibited significant 
inhibition. In addition, certain secretagogues were unaffected by FD preincubation, 
indicating that the pathway in which the stimuli activates the cell is critical to FD 
efficacy. That is, the FD does not result in a blanket protection of the cells response to all 
stimuli, but the FD specifically regulates specific signaling pathways. Mast cells and PBB 
responded differently to fullerene preincubation, suggesting that the signal transduction 
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pathways leading to mediator release are dissimilar as has been previously reported 
[127]. Further variation in how FD affected cell responses was demonstrated in the type 
of mediator release (degranulation, cytokine, prostaglandin production, or a combination 
thereof). Our strategy, including these studies, is to identify those FD that stabilize both 
IgE and non-IgE pathways and pursue more in depth toxicity, pharmacokinetic, and 
biodistribution studies. To this end, TGA is currently a top candidate demonstrating no 
toxicity in vitro and in vivo [22, 49]G#)'#,#E/.%*.#B(D,*#9S`Z""#'.,H)$)a%?#./#7-;<=#- 
dependent stimuli [22], prevents and reverses MC-dependent asthma in mouse models 
[32], and can inhibit non -7-;<=#?%'E/*'%'#,'#C%D/*'.?,.%C#B%?%)*0 
There were no clear structure-activity relationships that were established from 
these studies. Particular FD was more effective controllers of numerous stimuli, for 
example Tetrasulfonate showed statistically significant reductions in degranulation 
regardless of stimulant used. However, compounds such as CCC were only successful at 
blunting somatostatin-induced degranulation, while it did not have any effect on the 
mediator release elicited by any of the other compounds. Mechanistically, these 
compounds significantly prevented activation of MAPK and LAT suggesting they either 
block the signaling intermediates directly or some other intermediate upstream. The 
inhibition of mediator release by FD was paralleled by reductions in secretagogue-
induced elevations in ROS/calcium levels as well as the signaling intermediates MAPK 
and LAT. These findings are similar to those previously demonstrated when examining 
ROS/calcium levels and phosphorylation-/A#')+*,$)*+#)*.%?D%C),.%'#)*#7-;<=-challenged 
MC [20, 22]. Current studies are aimed at identifying potential intracellular binding 
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partners of FD similar to experiments performed to identify binding partners in response 
./#7-;<=#'.)D($('#[128]. 
Another example in our attempts to rationally designed FD for specific disease 
involves the role of MC in atherosclerosis. A link between MC activation and 
atherosclerosis has now been clearly demonstrated [103, 129] as their numbers are 
greatly increased in the intima at sites of arterial plaque rupture [129], in advanced plaque 
lesions in the carotid artery [130], and patients who died of acute myocardial infarction 
have an increased number of degranulated MCs at the actual site of plaque erosion or 
rupture [131]. Therapies aimed at treating atherosclerosis include niacin which blocks 
vascular inflammation, ROS, and inflammatory cytokine production in conjunction with 
diminishing NF-m"#,-.)&,.)/*#[132]. Thus, the niacin FD was constructed and 
demonstrated inhibition of mediator release from several non-IgE pathways through 
reduced cellular ROS and ERK1/2 phosphoactivation. Mast cell-stabilizing therapies 
such as Cromolyn have shown promise in ApoE models of atherosclerosis (the classic 
animal model for atherosclerosis) where it prevents intra-plaque hemorrhage [133]. Thus, 
strategies aimed at blocking MC activation before it occurs could represent a new 
strategy for treating atherosclerosis. 
Prostaglandin D2 is produced by MC and recruits Th2 cells, eosinophils, and PBB 
and it is critical to development of allergic diseases such as asthma [24]. In mammalian 
organs, large amounts of PGD2 are found only in the brain and in MC. Previous studies 
found MC-E?/C(-%C#Zn5O#)'#.B%#E?)D,?>#D%C),./?#/A#&,'/C)$,.,.)/*#2.B%#o*),-)*#A$('Bp6#
after ingestion of niacin (nicotinic acid) [41]. Previously reported data reveals that non-
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IgE induced PGD2 production was attenuated when ROS production was reduced [134]. 
This may be in part due to the mechanism that ROS facilitates the formation of a 
hydrogen bond necessary for PGD synthase activation [134]. In our study, the FD 
evaluated that was effective at reducing ROS generation in MC was also effective 
regulators of PGD2 production, possibly under the proposed mechanism of modulating 
PGD synthase activity. 
In conclusion, these studies further delineate the ability of FD to affect human 
MC and PBB responses so that diseases mediated by these cell types may be a target for 
FD-derived therapies. It is demonstrated that certain FD can differentially modulate 
mediator release from MC and PBB in response to a variety of secretagogues. This 
inhibition can involve the blunting of activation-induced increases in ROS, the release of 
intracellular stores of calcium, and the phospho-activation of MAPK and LAT. 
Furthermore, the inhibition is strictly governed by several factors, the degree and type of 
functionalization of the fullerene nanomaterials, the type of cells that are analyzed, the 
mediator being evaluated, and how the cell is being activated to illicit the mediator 
release. These studies further extend the utility of FD as inhibitors of MC mediator 
release and cytokine production through non-IgE mediated pathways. 
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CHAPTER IV 
FUNCTIONALIZED GADOLINIUM ENDOFULLERENES DETECT 
ATHEROSCLERTOIC PLAQUE LESIONS 
 
IV.1 Introduction 
Atherosclerotic cardiovascular disease results in close to 20 million deaths 
annually. A hallmark of the disease is the accumulation of plaque lesions in blood vessel 
walls which can rupture and result in acute myocardial infarction and stroke. Clearly 
better diagnostic tools are needed to identify incipient disease, monitor disease 
progression, and pinpoint factors that predict catastrophic ruptures.  
At present, it is difficult for physicians to specifically detect and quantify plaque 
lesion buildup in vessel walls. Cardiovascular magnetic resonance (CMR) is one of 
several techniques being investigated to identify plaque burden in patients so that 
interventions can be conducted before rupture occurs [135, 136]. We have used novel 
gadolinium (Gd)-containing C80 %*C/B%C?,$'#8?)D%.,'EB%?%'XG#894G#nC3N@C80) [137] 
as a platform to develop new atherosclerotic targeting contrast agents (ATCA) for CMR. 
The TMS-based molecules have 25 fold increased relaxivity compared to other contrast 
agents, reduced risk of metal toxicity, and can be customized to address issues 
surrounding solubility, specificity, etc. [71]. TMS were functionalized with highly 
specific ligands for the scavenger receptor CD36 found on the surface of macrophage 
foam cells in plaque lesions [79]. It is demonstrated that ATCA specifically bind to and 
are taken up within foam cells in vitro and are able to detect lesions in plaque-susceptible 
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mice )*#&)&/#2^E/$)E/E?/.%)*#@#C%A)-)%*.#D)-%#q^E/@#r`rs60#8B('G#894#-,*#H%#.,?+%.%C#
to specific biomarkers in sufficient quantities to provide enhanced imaging of 
atherosclerotic plaque under physiological conditions. These results suggest that the 
ATCA may be a new tool for detecting atherosclerotic plaque. 
IV.2 Methods 
IV.2.1 ATCA synthesis, functionalization, and characterization 
The method to synthesize the TMS uses an electric-arc process to encapsulate Gd 
within a carbonaceous cage, C80 [137], which was used as the starting material for the 
ATCA. The molecular weight of TMS (1,446 Da) was determined using matrix-assisted 
laser desorption/ionization (MALDI) with a time-of-flight (TOF) mass spectrometer. 
Elemental analysis determined that TMS contains 10.15 ± 0.25 mM Gd which 
approximates the value estimated from the molecular weight. No free Gd (Gd outside the 
carbon cage) was detected using an Arsenazo III colorimetric test [138] and ICP analysis 
of liquid after dialysis of the TMS. Further, atomic force microscopy (AFM) 
measurement of the TMS showed the majority of the nanoparticles are 1.1-1.3 nm in 
height with some particles approaching 3.0 nm to 4.0 nm, suggesting minimal 
agglomeration and/or aggregation. 
The ATCA was developed as shown in Appendix A in which the TMS is 
functionalized with hydrophilic and lipophilic groups [71] and incorporated into 
liposomes [48]. The resulting liposome-TMS were formulated with or without CD36 
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ligands intercalated within the liposome bilayer membrane [79, 139]. The ATCA was 
characterized as seen in Appendix B. 
IV.2.2 Cell culture 
 Foam cells were generated using oxidized-low density lipoproteins (oxLDL) from 
human plasma as described previously [140] and verified using oil red-o (ORO) staining 
[141]. The upregulation of CD36 expression in foam cells was confirmed using both PCR 
and FACs analysis with CD36-specific antibodies. As a control, the non CD36-
expressing cell line 3 T3-F442A pre-adipocytes were used to detect non-specific binding. 
8B%#]tPg#-%$$'#,*C#A/,D#-%$$'#R%?%#%K,D)*%C#A/?#./K)-).>#(')*+#(E#./#bcc#d+`D$#2A)&%#
times the amount used for in vivo studies) for 10 days. No significant differences in cell 
viability was observed with ATCA-treated cells compared to controls (not shown) which 
further supports the observation that derivatized fullerenes are not toxic in vitro [22, 49]. 
Cells were treated with CD36-targeted or non-targeted controls at various concentrations 
for 24 h, centrifuged and the supernatant saved for Gd analysis. After a quick wash the 
cell pellet was disrupted by sonication and supernatant and cell pellet subjected to ICP 
analysis or neutron bombardment (both methods gave similar results; not shown) to 
determine Gd concentration as described below. 
IV.2.3 Cell uptake of the ATCA revealed by FIB-SEM crossbeam microscopy 
 In order to examine cell uptake of the ATCA we used a Zeiss FIB-SEM 
crossbeam workstation. Foam cells were incubated with or without ATCA or non-
.,?+%.%C#-/*.?/$#2Oc#d+`D$6#Aor various times (16, 36, 72 h). As a control non-targeted 
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ATCA were incubated for the same times. In addition, non-foam cells were incubated 
with ATCA for 24 h. Cells were washed and fixed using 1% glutaraldehyde solution and 
0.1 M cacodylate buffer for 2.5 hrs at room temperature. Samples were mounted on a 
microscope slide covered in aluminum foil and subjected to graded EtOH incubations 
(60%-100%/10 min each) and stored in a desiccated environment until microscopic 
analysis. 
The mounted samples were put in the FIB-SEM crossbeam workstation, while a 
focused ion beam (FIB) was used to cut the cells and expose inner structure of the cell. 
Simultaneously, scanning electron microscope (SEM) was used to image the cross 
section milled via FIB, this is capable because both the ion beam and electron beam can 
focus on the exactly same area. The FIB was operated at 30 kV, 20 pA and SEM was 
operated at 1 kV to reduce potential beam charge and cell damage. A secondary electron 
detector was used to reveal morphology and energy. Additionally, the energy and angle 
selective backscattered electron (EsB) detector was applied to detect ATCA existence 
and spatial distribution with nanometer level resolution inside the cells, since heavy 
element Gd-containing C80 endohedrals will express themselves much brighter in EsB 
images if TMS exists. 
IV.2.4 Western blotting and quantification of CD36-specific phosphor-signaling 
intermediates 
 To confirm the specificity of CD36 ligand binding on the ATCA to the CD36 
receptor and examine the mechanisms underlying the interactions between the ATCA and 
 
!
56 
foam cells, Western blotting was used as described previously [108]. Following ATCA 
challenge, foam cells were lysed directly in boiling denaturing sample buffer consisting 
of tris-buffered saline with triton-X-100 (0.5%) and protease inhibitors. Proteins were 
separated on a 10% gels in tris-glycine SDS running buffer. Western blotting and image 
quantification was performed using the Odyssey Imaging System (LI-COR Biosciences). 
Band intensities were captured using the Odyssey scanner and bands quantified by 
measuring the number of pixels in each band using a box drawn for the same area of 
measurement for each separate blot. Band intensities were normalized for loading by 
C)&)C)*+#.B%#*(DH%?#/A#E)K%$'#)*#%,-B#H,*C#R).B#.B%#B/('%T%%E)*+#H,*C#)*.%*').>#2j-actin) 
on the same blot. 
IV.2.5 Flow cytometry 
In order to confirm the upregulation of CD36 expression on foam cells, U937 
cells (negative control) or PMA/oxLDL-transformed cells (foam cells) were washed with 
PBS/1% BSA, and blocked for 30 min at 4°C with a 1/500 dilution of normal human 
serum. The cells were washed and incubated with FITC-labeled anti-CD36-FITC, or 
FITC-labeled isotype control (BD Biosciences;10 d+`Dh6#A/?#/*%#B?0#,.#euS0#^A.%?#.B?%%#
R,'B%'G#-%$$'#R%?%#?%'('E%*C%C#)*#ecc#dh#/A#Z"40#8B%#D%,*#)*.%*').>#/A#A$(/?%'-%*-%#
was determined for at least 10,000 cells using a FACScan flow cytometer (BD 
Biosciences). All experiments were performed in duplicate. 
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IV.2.6 CMR study 
8B%#$%')/*'#)*#,?.%?)%'#/A#^E/@#r`r#D)-%#E?/+?%''#A?/D#A,..>#'.?%,T'#./#A/,D#-%$$-
containing plaque in a similar way as humans [80, 142]0#^E/@#r`r#D)-%#2OP#R%%T'Y#
female) and non-diseased controls were anesthetized initially with isoflurane (3%) and 
oxygen (3 L/min) in an induction chamber and kept under constant sedation via a nose 
cone while monitoring vital statistics as described [143]. CMR was performed blinded by 
personnel with no knowledge of targeted and non-targeted compounds. All animal studies 
were approved by Wake Forest School of Medicine Animal Care and Use Committee. 
IV.2.7 Signal enhancement measurement 
 Images acquired after the ATCA injection were examined for areas of hyper-
intensity in the aorta wall (selected at random). As a comparison whole aortas were 
analyzed. Regions appearing hyper-intense after ATCA injection were manually traced 
using ImageJ (nih.org). The contrast to noise ratio was calculated using a reference 
region of interest (ROI) next to the plaque lesion or of the whole aorta. The same regions 
were traced in the pre-ATCA injection image and in all the post-ATCA time point 
images. The contrast to noise was calculated using the same reference ROI and then the 
contrast-to-noise ratio (CNR) values were normalized to the pre-CA CNR value. The 
quantification of signal intensities were tabulated and analyzed for all variables and 
expressed as mean ± standard error (SE) from five separate animals per group (Figure 
4.1B and Figure 4.1C). The StatPlus (Analyst Soft, 2011) software was used to evaluate a 
two (group) ! two (time) analysis of variance (ANOVA) with repeated measures was 
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evaluated to analyze data. Tukey LSD post hoc tests were used to examine pair-wise 
differences. Significance was set at p < 0.05.  
 
              
Figure 4.1. ATCA can Detect Inflammatory Plaque In Vivo4#56789:9#;)<.#$=>#?@AB#
*CD:E-6(#?.-.#)*F.<0.1#)4G4#$HII#JE:HII#JK(#?)0L#5,M5#$076 and middle) or non-
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targeted control (bottom) and images acquired at the indicated times. Bar = 1.0 mm. 
Arrows indicate contrast agent binding to the plaque. A. Representative images 
from two (ATCA) or one (control) different mice injected with ATCA. B, C. 
Quantification of signal enhancement of ATCA. In B, the brightest voxels 
(approximately >10 spots/section) in the aorta wall from 5 separate animals were 
measured excluding artifact. The ratio of the Signal Intensity (SI) of the brightest 
voxel in the aorta wall to the SI of the (non-affected) myocardium for each time 
point was calculated. In C, the ratio of SI of the whole region lining the aorta wall to 
the SI of the (non-affected) myocardium was measured and the average signal 
intensity was recorded for 5 separate slices from each time-point. The SI-
enhanced/SI-myo ratio from each time point to its pre scan SI-enhanced/SI-myo 
ratio were normalized (prescan values = 1). Data is expressed as mean of 5 CMR 
slices ± SD (n = 5; animals/grp; * indicates significance (p<0.05). D. Plaque lesions 
express macrophages and CD36 receptors. Aortas were stained with H&E (left), rat 
anti-mouse CD36 (middle), rat anti-mouse CD68 (bottom) or non-specific rat IgG 
(nsIgG). Peroxidase-conjugated anti-rat Abs were added and developed using AEC. 
The brown staining represents CD36- or CD68-positive cells located in the plaque 
lesions. Results are representative of at least three separate aortas. 
 
IV.2.8 Histology, immunohistochemistry, and Gd detection in tissue 
 The aorta of each animal was removed and fixed in Tissue-Tek OCT (Miles, 
Elkhart, IN) and frozen with liquid nitrogen. The tissue was sectioned onto siloconized 
slides and histopathology assessed using hematoxylin for assessing plaque accumulation 
[144, 145]. To examine CD36 and CD68 expression on macrophages in the plaque 
lesions the tissue sections were fixed in Carnoys, embedded in parafilm, and tissue 
sections placed on microscopic slides and probed with antibodies to CD36 and CD68 
(both from Serotec) followed by horseradishconjugated secondary antibodies and 
developed using AEC as described previously [29, 146]. As a control nonspecific, 
isotype-matched control antibodies (for CD36 and CD68) were used. Images were 
captured using a camera-equipped Zeiss AXIO Observer. For tissue distribution of Gd, 
organs (or ATCA sample used to inject to determine total Gd counts) were weighed and 
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placed in pyrex tubes and combusted to ash at 900°C for 1 h. The samples were again 
weighed and resuspended in 1.0 ml of 12 M (37%) HCl. The Gd was measured using ICP 
and percent Gd in tissue calculated based on the total amount of Gd in the ATCA sample 
used for injections. 
IV.2.9 Toxicological evaluation 
 ^E/@#r`r#R%?%#)*v%-.%C#)0&0#R).B#Z"4#/?#bGccc#d+`bcc#d$#2bc#.)D%'#D/?%#.B,*#
optimized for imaging studies) of ATCA. Mice (four/group) were sacrificed at days two, 
seven, and 14 and alanine aminotranferease (ALT) and aspartate aminotransferase (AST) 
levels evaluated in serum. The ALT and AST are transaminase enzymes that leak out into 
the general circulation when the liver is injured. In separate experiments, ATCA were 
injected as above, tissue harvested at day seven, and subjected to neutron bombardment 
or ICP for Gd quantification. An aliquot of the ATCA (not injected) was measured 
separately to determine the percentage cleared from the mice. 
 
IV.3 Results 
 
IV.3.1 Plaque targeting contrast agents are selectively taken up by foam cells through 
CD36 receptor 
 Atherosclerotic plaque have higher numbers of macrophage foam cells that 
express CD36 scavenger receptors on their cell surface [147]. Given that the CD36 
actively uptake extracellular lipids into their cytoplasmic membrane [148], we 
hypothesized that this may be a way to incorporate the ATCA contrast agent into foam 
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cells in sufficient enough quantities that CMR could be performed. Foam cells were 
induced using PMA/oxLDL and the upregulation of CD36 expression was confirmed 
using FACs analysis (Figure 4.2A). As seen in Figure 4.2B, ATCA had a significant 
uptake into the CD36-expressing foam cells. The control compound for ATCA without 
the CD36 targeting moiety ligands (control) was not taken up within the cells suggesting 
the CD36 receptor was responsible for the uptake of the compounds within the cells. In 
data not shown, there was no uptake in non-foam cell monocytes or non-monocytic, 
tissue cells (3T3).  
 
 
Figure 4.2 - Upregulation of CD36 Receptors on Foam Cells. A. U937 cells (in 
duplicate) were treated as described in Methods, washed and incubated with 
antibodies to CD36 or an isotype matched control. The graph shows the average 
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mean fluorescent intensity (MFI) of the signal (±SD) and is representative of three 
separate experiments. B. Testing ATCA for foam cell binding. U937 cells (non-foam) 
were converted into foam cells (foam) using oxLDL and PMA as described. Cells 
?.-.#?/AL.1#/*1#5,M5#$HI#JE:;K(#/11.1#7G.-*)EL0#)*#/#MN2 incubator. The next 
day cells were washed with media and the supernatants (S) and pellets (P) subjected 
to ICP for Gd detection. The percentage of Gd in the pellet and supernatant was 
calculated based on the total amount added to the cells. 
 
We next used a FIB-SEM to follow the ATCA inside foam cells and determine 
the length of time it remains. Figure 4.3A-3H demonstrates that fullerene-based 
compounds can be detected inside human foam cells. The ATCA is shown to be more 
scattered inside the cell at earlier time points (Figure 4.B, D) and begins to aggregate 
with lesser amounts inside the cell at later time points (Figure 4.F) suggesting cell 
excretion. The non-targeted control was not detected inside the foam cells (Figure 4.G, 
H) further suggesting the specificity of the ATCA for foam cells. 
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Figure 4.3.  ATCA are Taken Up by Foam Cells. Foam cells were incubated with 
5,M5#$HI#JE:;KB#5-F) or non-targeted control (G,H) for 16 (A,B), 48 (C,D) or 72 
(E,F) hrs, washed, fixed, and subjected to FIB-SEM. Left columns (A,C,E,G) shows 
the morphology images taken by secondary electron detector after focused ion beam 
cut and the right column (B,D,F,H) shows the corresponding material contrast 
images taken by energy and angle selective backscattered electron (EsB) detector 
for the same region. The foam cell-targeted ATCA are clearly revealed inside the 
cells but not in the non-targeted controls. In parallel, an aliquot of cells were used to 
measure cell viability by trypan blue exclusion and revealed no cell death induced 
by ATCA addition compared to non-treated controls (not shown). 
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To definitively establish the specificity of ATCA binding to the CD36 receptor 
we used Western blotting and quantification of CD36-associated signaling molecules 
induced by ATCA treatment. Previous studies have shown that Erk, Lyn, and JNK2 are 
activated by the binding of oxLDL to CD36 receptors on macrophages [149, 150]. When 
foam cells were challenged with ATCA there was a dose (Figure 4.4A) and time (Figure 
4.4B) dependent activation of these signaling molecules. This provides definitive 
evidence that ATCA specifically target foam cells through CD36 receptors. 
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Figure 4.4.  ATCA Activate CD36-Specific Signaling Intermediates. Foam cells were 
incubated with or without varying concentrations of ATCA (A; dose response) for 
10 min 7-#?)0L#HI#JE:;K#5,M5#$OB#0);.#<7P-A.(#Q7-#G/-R)*E#0);.A4#M.KKA#?.-.#KRA.1#
and Western blotted using phospho-specific antibodies. Band intensities were 
quantified and the numbers represent the fold increase of each band compared to 
0L.#L7PA.@..6)*E#E.*.#3-actin which did not demonstrate any change upon ATCA 
challenge. Results are representative of three separate experiments. 
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IV.3.2 ATCA detect atherosclerotic plaque in vivo 
_%#('%C#^8S^#./#&)'(,$)a%#,.B%?/'-$%?/.)-#C)'%,'%#)*#^E/@#r`r#D)-%#[80]. As 
seen in Figure 4.1A (top and middle), mice injected i.v. with the ATCA had a striking 
enhanced T1 image of the plaque attached in the mouse aorta that could not be seen prior 
to injection. Of note is the observation that the imaging agent accumulates over time, 
suggesting it circulates through the blood for periods long enough for biomarker targeting 
to occur (data not shown). Control compounds without the CD36 ligands demonstrated 
*/#,--(D($,.)/*#)*#.B%#&%''%$#R,$$'#/A#^E/@#r`r#D)-%#27)+(?%#4.1A-bottom). 
Quantification of the imag%#)*.%*').>#/A#<L=F'#,EE%,?)*+#,A.%?#^8S^#)*v%-.)/*#27)+(?%#
4.1B) demonstrates accumulation of the compounds occurs after 30 min; one and two 
hour time-points demonstrated the optimal imaging time. When measuring the entire 
aorta the normalized mean intensity was very similar to what was observed in the bright 
'E/.#<L=F'#27)+(?%#4.1C). This quantification clearly demonstrates the ATCA 
significantly increases the contrast representing plaque lesions. 
Separate experiments were performed with non-diseased animals. In these 
experiments the ATCA and control were injected and the descending aorta imaged at the 
same time points. As seen in the bottom panels wildtype C57 mice did not demonstrate 
any signal enhancement in the descending aorta further demonstrating the specificity of 
the ATCA for plaque detection. These results suggest the ATCA specifically detect 
disease-induced plaque lesions that are not expressed in normal vessel walls. 
Histochemical evaluation of each animal revealed that plaque lesions were present in the 
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diseased animals (Figure 4.1D; left) with the accumulation of CD36-and CD68-positive 
cells on the anterior portion of the plaque lesions (Figure 4.1D; middle/bottom). 
IV.3.3 Tracking the in vivo fate and toxicity of plaque-targeting contrast agents 
 In order to determine the fate of the ATCA we performed whole body scans after 
i.v. injection as described above. In all experiments the injection was well tolerated in 
each group of mice with no noticeable adverse reactions observed. As determined using 
CMR, there was no accumulation of any of the compounds in any major organs (e.g. liver 
,*C#T)C*%>'6#,.#.B%#',D%#.)D%#E/)*.'#D%,'(?%C#)*#.B%#^E/@#r`r#D)-%#27)+(?%#4.5A). To 
confirm these results we performed ICP analysis on the organs of these animals after 
seven days post injection. As seen in Table 4.1 Gd was only detected in the liver and 
kidneys demonstrating that approximately 85% of the ATCA is excreted from the body at 
this time-point. 
 
Table 4.1. Total Percent Gadolinium in Tissue.  
 
                           
In separate experiments in which high concentrations of ATCA were injected, 
there was no significant increase in serum activity of ALT and AST between the 
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untreated and ATCA-treated animals indicating no liver toxicity (Figure 4.5B). Thus, the 
ATCA do not affect liver function and are mostly cleared from the body within five days 
after injection. 
 
 
Figure 4.5.  Plaque-Targeting Contrast Agents do not Accumulate in Major Organs. 
A. Representative plaque-targeting contrast agent and non-targeted control was 
injected as above and the mouse placed supine for whole body scan. Results are 
representative of four separate mice. B. C. ATCA does not accumulate in liver or 
induce toxicity. Mice were treated ?)0L#7-#?)0L7P0#HIII#JE:HII#JK#7Q#5,M5#G)/#0/)K#
vein injection. Two and six days later the serum was used for ALT and AST levels. 
Data is presented as an average of four (untreated) or four (treated) mice ± SD. No 
increase in activity was observed between the untreated and treated samples. 
Activity is measure by Units/L obtained using linear regression from a standard 
curve. 
 
IV.4 Conclusions 
 The results presented here demonstrate that atherosclerotic plaque can be detected 
in vivo using targeted, Gd-based molecular imaging nanomaterials and standard CMR 
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techniques. Our rationale for developing ATCA was driven by the need for new ways to 
diagnose blood vessel plaque burden with existing technologies such as CMR. It is well 
established that atherosclerotic plaque express high levels of CD36 receptors for which 
ligands have already been identified. Importantly, these receptors normally and actively 
internalize the ligands (oxLDL); a prerequisite for accumulation of sufficient levels so 
that enhanced contrast can be observed. It is shown that this strategy was successful in 
identifying new ATCA which may provide new tools for physicians to detect plaque 
buildup in patients. 
Magnetic resonance imaging is one of many techniques used to assess 
atherosclerotic plaque lesions in patients [151, 152]. We functionalized the TMS through 
the addition of CD36 ligands which were hypothesized to home to macrophage foam 
cells found in atherosclerotic plaque [75, 76, 153, 154]. Indeed, many studies have used 
this strategy of targeting diagnostics to macrophages through scavenger receptors as well 
as other macrophage-exp   ressed biomarkers through several techniques including CMR 
[72, 153, 155-164]. For example, the Fayad group investigated the ability of macrophage 
scavenger receptor-targeted immunomicelles to assess macrophages in atherosclerotic 
plaque using CMR in vivo. The targeted micelles increased the signal intensity of 
,.B%?/'-$%?/.)-#,/?.,'#gt:#)*#^E/@r`r#D)-%#-/DE,?%C#R).B#/*$>#Pe:#(')*+#(*.,?+%.%C#
controls [153]. Others have targeted macrophages through the use of Lyp-1 peptides 
attached to a fluorescent dye [164]. Thus, targeting macrophages in atherosclerotic 
lesions is a valid strategy for developing diagnostics capable of detecting and quantifying 
plaque lesions. The advantages of using the CD36 receptor for targeting CMR contrast 
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agents to plaque is its well established connection in atherosclerosis [75, 76], its high 
expression on plaque foam cells [76], and its ability to be  internalized upon ligand 
binding [165] which allows the accumulation of the ATCA ligand even under 
physiological flow conditions as was shown in Figure 4.1. The key limitation presently is 
the lack of a specific biomarker (or biomarkers) for plaque lesions that will not cross-
react with other sites in the body. An even more difficult challenge is identifying 
vulnerable plaque biomarkers. 
We used the Gd-containing TMS as they provide a unique starting material for 
developing biomarker-targeting diagnostics [166]. The TMS offers several advantages 
over current Gd-based CMR contrast agents for use as targeted diagnostics. First, the 
toxic Gd (in cage) is separated from active targeting moieties (outside cage) by the 
carbon shell. Adding targeting ligands/moieties to current contrast agents may affect the 
ability of Gd to become free of the compound. Of course, further studies are needed for 
these molecular entities but we and others have not observed any toxicity of empty cage 
or TMS (Figure 4.5) using several in vitro and in vivo assays [32, 49, 167]. Second, the 
TMS are more sensitive than existing contrast agents with three Gd/molecule compared 
to one Gd/molecule in commercially available chelates [166]. Targeted imaging agents 
require strong signals by which to report the presence of an agent at a particular location. 
Third, the fullerene cage can be targeted to disease biomarkers or encapsulated into 
liposomes/micelles without compromising release of Gd into the body; a strategy already 
being used for targeting glioblastoma [168]. The chemistry for the addition of different 
moieties to the cage offers many possibilities for not only biomarker targeting of plaque 
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accumulation but also detection of biomarkers associated with removal of lesions (e.g. 
peptidoglycans) so that new tools for evaluative diagnosis of this disease can be 
developed.  
The specificity of the ATCA for targeting foam cells through CD36 is 
demonstrated three separate ways. First, ICP analysis of Gd within foam cells was 
confirmed in Figure 4.2B demonstrating that the CD36-ligand-decorated ATCA were 
significantly taken up within foam cells while the non-targeted ATCA were not. Second, 
we used FIB-SEM; a powerful technology that can be used to cut the cell open and detect 
nanomaterials, to further show the targeted ATCA is specifically internalized within foam 
cells were levels begin to diminish after 72 h. This suggests the cells remain viable and 
can continue to exocytose as a normal macrophage would. Third, we show the targeted 
ATCA, and not the non-targeted, specifically activate signal transduction intermediates in 
the CD36 receptor pathway including the ligand binding-dependent phosphorylation of 
Erk, Lyn, and Jnk. Thus, the ATCA specifically detects and is taken up by macrophage 
foam cells though the CD36 receptor. 
8B%#('%#/A#^E/@#r`r#D)-%#./#'.(C>#S9<#-/*.?,'.#,+%*.'#B,'#H%%*#C%'-?)H%C#
extensively [80, 142]. We demonstrate that the ATCA specifically recognize 
atherosclerotic plaque in diseased animals. No contrast was observed with non-targeted 
controls or in ATCA-treated, non-diseased animals. The signal enhancement occurs in a 
time-dependent fashion suggesting the foam cells are actively internalizing the ATCA via 
the CD36 scavenger receptor. While it has been reported that the lesion burden can vary 
among animals it was demonstrated that each animal tested had high levels of plaque 
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lesions containing macrophages and CD36 receptors as identified using histochemistry 
and immunohistochemistry (Figure 4.1D). While each animal was verified to contain 
inflammation one limitation of this study was the small numbers of animals used. We are 
in the process of verifying these results in higher-order mammals (rabbits). The high 
power 7 T scanner used warrants further validation of the ATCA in a more clinically 
relevant scanner. However, the TMS have been studied in lower field magnets and 
demonstrate similar relaxivity and sensitivity [169, 170]. 
Investigation of biocompatibility and biodistribution of the TMS-based protein 
cages in vivo is critical for future clinical translation. To this end, the studies examining 
the toxicity of fullerenes on human systems are still emerging and the subject of debate 
[167, 171]. Several in vivo publications suggest that (in general) fullerenes show no overt 
signs of toxicity up to 2000 mg/kg [99, 100] and have been shown to extend the lives 
(11%) and improve cognitive function of mice chronically treated with these compounds 
[17]. More recently, rats given fullerenes in olive oil lived over 90% longer than control 
mice [18]. We demonstrated that a single dose of ATCA, given at a 100 fold 
concentration higher than that needed for plaque imaging in vivo, caused no overt signs 
of toxicity, does not accumulate in the liver, and does not induce liver damage. These 
results are consistent with the observation that TMS injected i.v. into mice is passed 
through the kidney and into the urine (data not shown). The ATCA is mostly cleared 
from the body after seven days as demonstrated above. Similarly, the TMS were recently 
shown to have a favorable toxicity profile in vitro and in vivo [49]. Since it is anticipated 
that a patient will only be given a single injection before CMR is performed, these results 
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are encouraging for future studies in humans. However, more studies are clearly needed 
to examine the long-term effects of fullerenes on biological systems. Efforts are focused 
on systematically identifying any acute and long-term toxicity issues with ATCA. 
This study describes the synthesis and testing of a new class of ATCA based on a 
novel metallofullerene nanomaterial. In vitro screening was used to select high relaxivity 
compounds that were taken up by foam cells via the scavenger receptor CD36. The CD36 
-/DE/(*C'#R%?%#'B/R*#./#.,?+%.#)*A$,DD,./?>#$%')/*'#)*#^E/@#r`r#D)-%#RB)$%#.B%#',D%#
compounds without the CD36 ligands did not. These and other similar studies discussed 
above suggest the rationale for targeting macrophage foam cell may provide physicians 
with new tools for non-invasively diagnosing and quantifying otherwise undetectable 
plaque lesions. These results also suggest the TMS may serve as a platform to attach 
other biomarkers to target and image disease-specific biomarkers. 
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CHAPTER V 
A STEROID-MIMICKING FULLERENE THAT MEDIATES INHIBITION OF 
HUMAN LUNG MAST CELL RESPONES 
 
V.1 Introduction 
The use of corticosteroids (also known as glucocorticosteroids, glucocorticoids, or 
steroids) is the hallmark treatment for patients suffering from many chronic inflammatory 
and immune diseases (such as asthma) yet the treatment response is extremely variable 
among patients. Specific subsets of patients are nonresponsive to such treatments and are 
termed steroid resistant. These patients often fail to respond to even extremely high 
dosages of inhaled corticosteroids (ICS), therefore much research has been focused on 
understanding the mechanisms of ICS action to better understand non-responsive patients 
[172]. Several different studies have found that the dual-specificity phosphatase 1 
(DUSP1) is a prospective regulator of this ICS response [173-177]. Dual-specificity 
phosphatase 1 is one in a family of protein phosphatases which has been shown in vitro to 
inactivate mitogen-activated protein kinases (MAPK) [174]. Upregulation of DUSP1 
directly results in the de-phosphorylation/inactivation of mitogen-activated protein kinase 
(MAPK) via dephosphorylation of the threonine and/or tyrosine residues and thus acts as 
a regulator through a negative feedback mechanism [178-180]. The induction of the 
USP1 gene and subsequent inhibition of MAPKs result in the reduced expression of pro-
inflammatory cytokines [181-183]. 
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While ICS therapy remains a successful first line treatment for persistent cases of 
asthma, consistent use of steroids can have many harmful side effects. In addition, 
polymorphisms in DUSP1 expression are associated with clinical effectiveness of ICS 
therapy for asthma [175]0#7/?#E,.)%*.'#*/*?%'E/*')&%#./#=S4#.B%?,E>#jO-adrenergic 
receptor agonists are used. However, the link between DUSP1 expression and patient 
?%'E/*'%'#./#=S4`jO-adrenergic receptor agonists is not completely understood. Many cell 
types respond to steroids by upregulating DUSP1, which dephosphorylates and 
inactivates both MAPK and JNK resulting in significant reductions in mediator release 
and the production of pro-inflammatory cytokines. 
Lung mast cells (MC) are effector cells in the asthmatic response [23] and release 
of their asthma-triggering mediators has been shown to be inhibited by steroids [184, 
185] ,*C#jO-adrenergic receptor agonists [186]. The role of DUSP1 expression in 
activated human lung MC following pharmacological interventions has not been studied. 
Clues for a role for DUSP1 in MC-driven responses came from studies where MC from 
knockout mice lacking DUSP1 show enhanced degranulation and are highly susceptible 
to anaphylaxis [187]. Mast cell stabilizing nanomaterials were also shown to increase 
DUSP1 gene expression which paralleled inhibition of mediator release [22]. Based upon 
these similarities, we investigated the mechanism underlying C70-Tetrainositol (C70-I) 
inhibition of lung MC mediator release and compare its effects to those of steroids and 
jO-adrenergic receptor agonists. As shown below C70-=#)*B)H).%C#H/.B#7-;<=-mediated 
degranulation and GM-CSF cytokine production which was paralleled with increases in 
DUSP1 expression. Furthermore, C70-I synergized with long-acti*+#jO-adrenergic 
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receptor agonists (LABA) to potentiate this inhibition. These findings provide 
mechanistic insight into how C70-I can mediate MC degranulation and cytokine 
production and how DUSP1 polymorphisms could influence varying responses in patient 
ICS treatment [175] through the upregulation of lung MC DUSP1 levels. 
V.2 Methods 
V.2.1 Fullerenes synthesis and characterization 
The C70-I was synthesized by conjugating four myo-inositol molecules (cis-
1,2,3,5-trans-4,6-cyclohexanehexol) to each C70-carbon cage via BingelWHirsch 
cyclopropanation reaction [48, 188, 189]. C70-I has two inositol moieties at each of the 
two poles of the oval-shaped C70 molecule. These myo-inositol moieties solubilize the 
C70 molecule in aqueous media. Myo-inositol has been shown to significantly reduce 
inflammation in two widely used animal models for inflammation [190]. The final 
compound was characterized using matrix assisted laser desorption ionization mass 
spectrometry (MALDI-MS), nuclear magnetic resonance (1H and 13C NMR), high-
performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy 
278=<6G#,*C#C>*,D)-#$)+B.#'-,..%?`a%.,#E/.%*.),$#25h4`w60#S70-I was found to be 
approximately 30 nm in diameter and fully dispersed in buffered saline, it has a 
D/$%-($,?#A/?D($,#/A#SbccMeeLPO#R).B#9_#/A#bgVx#5,G#,*C#,#a%.,#E/.%*.),$#/A#rbx0tc#
mV (Appendix A). Additionally, cell toxicity was assessed by incubation with 
concentrations shown effective for inhibition (10rf, 10rg, 10rx, and 10rV M) and viability 
counts taken on days three, six, and nine. No toxicity was observed using trypan blue 
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exclusions compared to control cells (Appendix A). Pre-incubation of MC with a 
fluorophore tagged-C70-I (Texas Red) revealed uptake of fullerenes by MC with high 
efficiency at concentrations down to 10rbc M after 5 h of incubation (Appendix A). 
V.2.2 Gene microarray 
 Mast cells were harvested from tissue received by the Cooperative Human Tissue 
Network and cultured using methods previously described [24W26]. Mast cells (N95%; 1 
! 107 cell/condition; each condition performed in triplicate) were incubated with or 
without C70-I (10
rV M for 16 h; 37°C; 6% CO2), washed in fresh warm (37°C) media and 
supernatants removed (to remove pre-formed mediators), and fresh warm medium alone 
(negative) or medium containing anti-7-;<=#^H'#2b#dg/ml) added for two hours at 37°C. 
Cells were centrifuged, the supernatant and the pellet immediately frozen and microarray 
performed using the Human Whole n%*/D%#L*%^??,>X#+%*%#%KE?%'')/*#E?/A)$)*+#
service (Phalanx Biotech Group) report. Microarray analysis was performed and analyzed 
as described previously [22]. The UNCG Human Studies International Review Board 
approved all studies. 
V.2.3 Immuno-blotting and immuno-precipitation 
 Mast cells (~ 3.0 ! 106 cells/ml) were pretreated with or without C70-I and either 
cross-linked with anti-7-;<=#^H'#2c0V#d+`D$6#/?#$%A.#(*.?%,.%C#)*#,#PguS#)*-(H,./?#R).B#
6% CO2. Cells were lysed using methods previously described [48, 105, 106, 191]. For 
immuno-precipitations (IP), lysates were pre-cleared with Protein A/G agarose beads, 
followed by overnight incubation with anti-DUSP1 (Abcam, Cambridge, MA) 
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conjugated beads at 4°C and washed extensively to isolate DUSP1 proteins. Precipitates 
were subjected to SDS-PAGE (10% SDS gels; Life Technologies, Grand Island, NY) and 
immuno-blotting (IB) as described [106]. For highly efficient and quantitative exposure, 
IR700 or IR800--/*v(+,.%C#'%-/*C,?>#,*.)H/C)%'#R%?%#D%,'(?%C#(')*+#h)-/?F'#LC>''%>#
infrared imaging system (Licor Inc. Lincoln, NE). The band intensities were quantified as 
described [192] and normalized to the house-T%%E)*+#+%*%G#j-actin.  
V.2.4 Mast cell mediator release 
 Lung MC of the MCT (tryptase-positive, chymase-negative; predominant type 
seen in the alveoli of the lung N93%) [193] were incubated for 16 h with or without C70-I 
and ICS alone (at increasing dosages to evaluate dose response), or in combination with 
jO-adrenergic receptor agonists or both overnight (16 h; 37°C; 6% CO2). Cells were 
washed ,*C#,-.)&,.%C#R).B#/E.)D,$#-/*-%*.?,.)/*'#2c0V#d+`D$6#/A#,*.)-7-;<=#^H'#2P"e6#
for 2 h 2j-Hex) or 16 h (cytokines) at 37°C. Mediator release was measured as described 
previously [105, 194]. Incubation times and concentrations were previously optimized 
and it was determined that 70-carbon fullerenes were taken up by MC through an 
endocytosis-dependent mechanism and persisted in the MC for up to one week, 
predominantly homing to the ER, but also to a lesser degree found in the mitochondria 
and lysosomes [21]. 
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V.3 Results 
V.3.1 Pretreatment of mast cells with fullerenes upregulates DUSP1 gene and protein 
levels 
9)-?/,??,>#,*,$>')'#R,'#('%C#./#/H.,)*#,#H?/,C#/&%?&)%R#/A#.B/'%#7-;<=-
associated signaling molecules influenced by C70-I pre-)*-(H,.)/*#A/$$/R)*+#7-;<=#
activation [22]. Interestingly, C70-I caused a dramatic increase in expression of wide 
range of genes, including several within the DUSP family. Notably, DUSP1 increased 
relative gene expression levels approximately 55% compared to cells that were not cross-
linked w).B#7-;<=0#S%$$'#E?%-incubated with C70-I (10
rV M) for 16 h prior to activation 
increased gene expression to approximately 155% (Figure 5.1A). Next, a dose response 
was performed to find the optimal concentration of C70-I that could affect the protein 
expression of DUSP1 in MC. Cells incubated with C70-I at 10
rV M were found to 
maximally increase DUSP1 protein expression (Figure 5.1B). These data were further 
supported by IB of the DUSP1 protein at 2, 4, and 6 h, where the pre-incubation of MC 
with C70-I markedly increased protein expression by nearly 99% at 4 and 6 h (Figure 
5.1C). Therefore, the MC inhibition observed with C70-I was paralleled by significant 
increases in DUSP1 expression. 
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Figure 5.1. Mast Cell Pretreatment with C70-I Increases DUSP1 Gene and DUSP1 
Protein Expression. Fullerene (C70-I [10
9D
 M) treated and untreated MC were 
<L/KK.*E.1#?)0L#$ST(#7-#?)0L7P0#$9(#/*0)-+<UVW#$H#JE:;K(#Q7-#2 h. Cell pellets from 
each condition in triplicates were used for RNA isolation and gene microarray as 
described. Gene microarray data conduction by Phalynx Biotechnology (A) 
demonstrates the increases in mean relative intensities of DUSP1 gene expression 
increases in C70-I pretreated samples (P b 0.005; ±SD of six observed values). To 
evaluate dose responses of C70-I (B), MC were pretreated with C70-I (10
9X
-10
9D
 M) 
and lysed as described. The lysates were immuno-blotted with polyclonal rabbit-
anti-'2&YH#/*0)Z71).A#$H#JE:;K(#/*1#6-7Z.1#7*#0L. Odyssey infrared imaging 
system with anti-rabbit IR800 secondary antibodies (results typical in three separate 
immuno-blots). Relative pixel intensity (green bar graph) of the IR800 protein band 
expression of DUSP1 was quantified and normalized (Licor Odyssey imaging 
software) to the house-@..6)*E#E.*.[#3-Actin to ensure equal protein levels were 
loaded into each lane (red band). To evaluate time course effects of C70-I (C), MC 
were cross-K)*@.1#?)0L#$ST(#7-#?)0L7P0#$9( anti-+<UVW#$H#JE:;K(#Q7-#2, 4, or 6 h and 
immuno-blotted as described in (B). 
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V.3.2 Fullerene upregulation of DUSP1 protein expression modulates activation of 
MAPK 
 To further understand the correlation between DUSP1 expression and MC 
inhibition with C70-I, experiments were performed examining DUSP1 downstream 
targets. Given that increases in DUSP1 activity will directly result in reduction of MAPK 
via de-phosphorylation of threonine and/or tyrosine residues, protein analysis of 
phosphorylated MAPK (p-MAPK) levels in C70-I MC pretreated with 10
rV M (the 
concentration that maximally activated DUSP1 protein expression; Figure 5.1) was 
performed. As expected, phosphorylation of MAPK was dramatically reduced at the four 
and six hour time points (Figure 5.2A); the same time points that showed significant 
increase in DUSP1 expression (Figure 5.1C). At 6 h phosphorylation of MAPK was 
nearly 80% lower in cells treated with C70-I as opposed to those that remained untreated 
(Figure 5.2B) indicating the C70-I-induced upregulation of DUSP1 directly results in de-
phosphorylation of MAPK in MC. These results suggest that increases in DUSP1 from 
C70-I directly prevent phosphorylation of MAPK which is crucial for MC activation 
leading to mediator release. 
 
!
82 
 
Figure 5.2. Mast Cell Pretreatment with C70-I Decreases Phosphorylation of 
MAPK1. Mast cells were pretreated with or without C70-I (10
9D
 M), washed, and 
<L/KK.*E.1#?)0L#$ST(#7-#?)0L7P0#$9(#/*0)-+<UVW#$H#JE:;K(#Q7-#2, 4, or 6 h. Lysates 
were immuno-blotted with polyclonal rabbit-antiphospho-MAPK1 antibodies (1 
Jg/ml) and probed on the Odyssey infrared imaging system with anti-rabbit IR800 
secondary antibodies (A). Relative pixel intensity of the IR800 phospho-MAPK1 
protein band (green band and bar graph) and IR700 house-@..6)*E#E.*.[#3-Actin 
(red band and bar graph) was quantified. Percent reduction of MAPK1 in untreated 
MC and C70-I pretreated MC was normalized to the house-keeping gene and pixel 
density of was calculated (B). Results are typical of three separate immuno-blots. In 
(C) cells were immuno-precipitated with anti-DUSP1 antibodies, run on SDS-
PAGE, and blotted with the indicated antibodies. 
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To delineate the possible mechanism of action that C70-I inhibits phosphorylation 
of MAPK and subsequent cell activation, activated cells were subjected to immuno-
precipitation (IP) with anti-DUSP1 antibody, followed by immuno-blotting (IB) with 
anti-ubiquiton (Ub), anti-phospo-MAPK, or anti-j-^-.)*0#=*#7-;<=-crosslinked cells 
DUSP1 protein was highly ubiquitinated (Figure 5.2C; compare lane one vs. lane two) 
which provides for a negative feedback mechanism for inhibition in other cell types 
[195]. However, when pre-incubated with C70-I there was a dramatic reduction in DUSP1 
ubiquitination (Figure 5.2C; lane 3). These data indicate that the increased DUSP1 levels 
(and subsequent decrease in MAPK levels) in cells pre-incubated with C70-I are due to 
the inhibition of DUSP1 ubiquitination and subsequent degradation through the ubiquitin-
proteasome pathway. 
V.3.3 Fullerenes and corticosteroids inhibit FCeRI-mediated-MC degranulation 
 Inhaled corticosteroids can also inhibit MC mediator release, but certain asthmatic 
patients are less responsive to ICS, due potentially to DUSP1 polymorphisms. Thus, 
based on the results suggesting a DUSP1-dependent inhibition of lung MC using C70-I, 
'%&%?,$#-/DD/*$>#('%C#=S4#R%?%#-/DE,?%C#)*#.B%)?#,H)$).>#./#)*B)H).#7-;<=-mediator 
release. A battery of ICS was initially evaluated (data not shown) and revealed that 
fluticasone and budesonide had the most significant impact on blunting mediator release 
from MC, therefore comparative studies were conducted on these two specific ICS. C70-I 
(10rg-10rV M) and fluticasone or budesonide ICS (10rx and 10rV M) were capable of 
significantly reducing MC degranulation without affecting cell viability (N95% using 
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trypan blue exclusion) compared to their untreated counterparts (Table 5.1). Optimal 
inhibition was observed with 10rV M pretreatments of fluticasone, budesonide, and C70-I 
resulting in inhibitions of 55%, 48%, and 68% respectively. Higher doses did not increase 
inhibition and resulted in some loss in cellular viability. These data demonstrate that C70-I 
is capable and comparable to ICS mono-.B%?,E>#)*#E?%&%*.)*+#B(D,*#$(*+#9S#7-;<=-
mediated degranulation. 
 
Table 5.1. \./*#]#+<UVW-Mediated Degranulation in C70-I or ICS (Fluticasone or 
Budesonide) Treated and Untreated Lung MC. 
 
                  
5,.,#'B/R*#,?%#D%,*#3#'.,*C,?C#%??/?#240@06#/A#j-M%K#?%$%,'%#,*C#E%?-%*.#)*B)H).)/*#/A#j-Hex release 
compared to untreated, activated MC. Results are representative of three different experiments in 
triplicates.  
ICS: Inhaled corticosteroid; MC: Mast Cell; M: Molar. 
* P<0.05. 
** P<0.005. 
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V.3.4 Co-incubations of fullerenes or corticosteroids with long-acting beta2-adrenergic 
receptor agonists inhibits FCeRI-mediated-MC degranulation 
 Combination techniques of ICS and LABA are commonly used by physicians to 
treat patients suffering from persistent asthma. Given the ability of C70-I to inhibit MC 
inflammatory mediator release through a DUSP1 mechanism and that patient responses 
to ICS are mediated by DUSP1 the next aim was to investigate the ability of C70-I to 
synergize with the LABA. Several LABA were investigated at different concentrations, 
the most efficient inhibitor LABA inhibitor, salmeterol, was selected for synergistic 
studies. As anticipated, MC treated with C70-I or ICS combined with LABA (dual-agent 
approach) revealed increased inhibition of degranulation compared to the single-agent 
approach. A side-by-side comparison of C70-I and LABA or ICS and LABA combinatory 
incubation with MC is illustrated in Table 5.2. The dual treatment response resulted in 
optimal inhibition of degranulation at concentrations of 10rV M fluticasone, budesonide, 
or C70-I co-incubated with 10
rV M salmeterol with statistically significant inhibitions of 
59%, 57%, and 75% respectively, on average an increased inhibition of cellular 
degranulation by 7% compared to the single-agent approach. Figure 5.3 represents a 
comparison of the single-agent (either ICS or C70-I alone) and dual-agent (ICS and 
LABA or C70-I and LABA) approach validating C70-I as a potential alternative to 
traditional ICS approaches for asthma therapy aimed at reducing lung MC hyper-
?%,-.)&).>0#=*#,CC).)/*G#.B%'%#C,.,#)$$('.?,.%#H/.B#-/DE/(*C'F#'>*%?+)'.)-#,H)$).)%'#R).B#.B%#
h^"^#',$D%.%?/$#./#E?%&%*.#7-;<=-mediated lung MC degranulation. Although, 
statistical evaluation of the single-agent versus dual-agent approach did not approach 
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significance, it was observed that inhibition was improved in most cases when MC were 
treated synergistically with LABAs and/or fullerenes/ICS. However, the evaluation 
fullerenes and LABA against ICS (fluticasone or budesonide) and LABA at a 
concentration of 10rg M produced statistically significant results (¥; in Figure 5.3), 
indicating that the fullerene molecule may be useful in blunting degranulation with 
similar efficiency to ICS. 
 
Table 5.2. &R*.-E)A0)<#8QQ.<0A#7*#]#+<UVW-Mediated Degranulation in Fullerene 
(C70-I) and LABA (Salmeterol) or ICS (Fluticasone or Budesonide) and LABA 
(Salmeterol) Treated and Untreated MC. 
 
                 
5,.,# 'B/R*# ,?%# D%,*# 3# '.,*C,?C# %??/?# 240@06# /A# j-M%K# ?%$%,'%# ,*C# E%?-%*.# )*B)H).)/*# /A# j-Hex release 
compared to untreated, activated MC. Results are representative of three different experiments in 
triplicates. 
ICS: Inhaled corticosteroid; MC: Mast Cell; M: Molar. 
* P<0.05. 
** P<0.005. 
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Figure 5.3.  The Effects of MC Pretreatment with C70-I/ICS Individually or in 
Combination with LABA on Degranulation. MC were cultured with C70-I, 
fluticasone, or budesonide (10
9X
-10
9D
 M) or C70-I, fluticasone, or budesonide at 
(10
9X
-10
9D
 M;) in combination with salmeterol (10
9D#
M); each pretreatment condition 
as well as untreated MC controls (Spontaneous and Positive) was challenged with 
$ST(#7-#?)0L7P0#$9(#/*0)-+<UVW#$H#JE:;K(#Q7-#>I#;)*#/0#>^#_M#/*1#AP6.-*/0/*0A were 
collected to measure degranulation as described in Methods. All studies were 
performed using at least three separate MC donor cultures in triplicates. Statistical 
significance indicated with * (P<0.05) and ** (P<I4IH(#PA)*E#0L.#&0P1.*0`A#0#0.A0#07#
<7;6/-.#-.A6.<0)G.#0-./0;.*0#07#P*0-./0.1#67A)0)G.#$+<UVW( controls. Statistical 
significance indicated with ¥ (P<0.05) using the StP1.*0`A#0#0.A0#07#<7;6/-.#.QQ)</<R#
ICS versus fullerene treatment at respective concentrations. 
 
V.3.5 Fullerenes and corticosteroids inhibit FCeRi-mediated-MC GM-CSF cytokine 
production 
 Mast cells produce GM-CSF in response to inflammatory stimuli; it is observed 
that ICS therapy can suppress the release of inflammatory mediators.1 Therefore, the 
ability of C70-=#,*C#=S4#./#?%C(-%#$(*+#9S#7-;<=-mediated-GM-CSF release was 
investigated. C70-I/ICS were evaluated separately and in 
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conjunction with a LABA. As expected, ICS pre-incubation resulted in a dose dependent, 
statistically significant reduction in mediator release when compared to untreated controls 
(Figure 5.4A). Pre-incubation with C70-I at increasing doses resulted in greater inhibition 
of mediator release than observed in ICS treatments at similar concentrations (Figure 
5.4A). The synergistic effect of ICS/C70-I co-incubation with LABA resulted in greater 
inhibition of GM-CSF production (Figure 5.4B), just as observed in the degranulation 
assays. A comparison of the single-agent and dual-agent approach is depicted in Figure 
5.4C demonstrating that C70-I has similar GM-CSF suppressive abilities as traditional 
ICS, as well as an ability to synergize with LABA to further inhibit cytokine production. 
Albeit, as was observed in the degranulation studies statistical significance was not 
revealed when comparing the single-agent and dual-agent therapies, it was found that 
lower concentrations of C70-I (10
rf and 10rg M) with or without LABAs produced 
statistically significant inhibition when compared to the equivalent ICS 
(with or without LABA) treatment (¥, Figure 5.4C). 
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Figure 5.4 - The Effects of MC Pretreatment with C70-I/ICS Individually or in 
Combination with LABA on GM-CSF Cytokine Production. MC were cultured with 
C70-I, fluticasone, or budesonide at (10
9X
-10
9D
 M) (A) orC70-I, fluticasone, or 
budesonide at (10
9X
-10
9D
 M) in combination with salmeterol (10
9D
 M) (B); each 
pretreatment condition as well as untreated MC controls (Spontaneous and Positive) 
?/A#<L/KK.*E.1#?)0L#$ST(#7-#?)0L7P0#$9(#/*0)-F<UVW#$H#JE:;K(#Q7-#>I#;)*#/0#>^°C 
and supernatants were collected to measure mediator release as described. Values 
are presented as total mediator release ng/ml and are representative of three 
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experiments analyzed in triplicate. Percent inhibition of GM-CSF production of 
fullerene/ICS alone (white bar) and fullerene/ICS in combination with LABA is 
displayed in (C) Statistical significance indicated with * (P<0.05) and ** (P<0.01) 
PA)*E#0L.#&0P1.*0`A#0#0.A0#07#<7;6/-.#-.A6.<0)G.#0-./0;.*0#07#P*0-./0.1#67A)0)G.#
$+<UVW(#<7*0-7KA4 Statistical significance indicated with ¥ (P<0.05) using the 
&0P1.*0`A#0#0.A0#07#<7;6/-.#.QQ)</<R#7Q#WM&#G.-APA#QPKK.-.*.#0-./0;.*0#/0#-.A6.<0)G.#
concentrations. 
 
 
V.4 Conclusions 
  
Inhaled corticosteroids are regarded as the hallmark treatment for patients 
suffering from asthma. Their beneficial effect has been shown to be due in part to the 
inhibition of proinflammatory genes. Mast cells play a key role in IgE-dependent 
inflammatory diseases such as asthma. In many cases, MC mediate both the sustained 
and immediate inflammatory responses via degranulation and production of cytokines. 
Stimulation through the IgE-?%-%E./?G#7-;<=G#?%'($.'#)*#.B%#,-.)&,.)/*#/A#9^Zy#,*C#
subsequently induces degranulation of preformed inflammatory mediators. The role that 
ICS play in modulating MC activation is of much interest, yet a defined understanding of 
the inhibitory mechanism of ICS at the cellular level has not been established. However, 
one protein, DUSP1, has been given significant attention [172, 177, 181] Here it is shown 
that C70-I upregulates the DUSP1 gene in human lung MC resulting in higher protein 
levels and lower MAPK activation through an ubiquitination pathway. Furthermore, 
combinatory treatments of ICS and LABA can further inhibit MC activation and similar 
inhibition was observed when pre-treating with C70-I, instead of ICS. 
 Part of the impetus for these studies was the often unpredictable and varied side 
effects of ICS in asthma patients [196] as well as the donor variability in the benefit of 
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ICS in some patients [175]. This has led to efforts to separate the desired anti-
inflammatory effects of ICS [197] and better understand the link between DUSP1 
polymorphisms and their link between asthma lung function. Our studies have 
demonstrated that fullerenes are not toxic in vitro or in vivo [32, 49, 198, 199] but instead 
have an overall anti-inflammatory effect. Additionally, fullerene uptake is not receptor 
mediated, however it is endocytosed by the cell [21]. Given that this anti-inflammatory 
effect is now demonstrated in human lung MC, both alone and in synergy with LABA, 
they may provide an alternative to ICS for patients that are steroid resistant without the 
unwanted side effects observed in high-dosage therapies. It is established the anti-
inflammatory actions of ICS are known to modulate gene expression via the 
glucocorticoid receptor (GR) [181]. Side effects of ICS are commonly attributed to gene 
induction by ligand-activated GRs [181]. While the ICS treatment strategy is deemed an 
extremely potent anti-inflammatory therapy, their use often comes with some reticence 
from physicians due to the range and severity of their side effects. Furthermore, it has 
been shown that mutated GRs have failed to activate the ICS response in a subset of 
patients [181]. Consequently, the non-receptor mediated mechanism of fullerenes may 
kinetically favor therapeutic intervention in cases of patients that fail to respond 
adequately or inversely to traditional ICS treatment regimes. Additionally, the differences 
in mechanisms between C70-I and ICS, although still in need of further investigation, may 
be advantageous for a C70-I-inspired therapy through a decrease in ICS-associated side 
effects. 
 
!
92 
 As a protein tyrosine phosphatase, DUSP1 is known to modulate immune 
responses. Specifically, DUSP1 is considered an ICS-induced phosphatase that is capable 
of inhibiting phosphorylation of MAPK in MC as first identified by Kassel et al. [200]. 
Furthermore, clinical effectiveness of ICS in patients with DUSP1 polymorphisms can be 
variable, suggesting that new therapies should be examined to help better control disease 
progression [175]. The C70-I was capable of increasing both gene expression and protein 
levels of the inhibitory regulator DUSP1, just as in ICS therapies. Pre-incubation of 
7-;<=#-B,$$%*+%C#9S#R).B#S70-I resulted in greater than a 50% upregulation of DUSP1 
gene expression when compared to those untreated, which was analogous to high levels 
of DUSP1 protein expression in challenged MC at early (4 and 6 h) time-points. As 
expected, the upregulation of DUSP1 caused significant (greater than 65%) reductions in 
MAPK activation at these same time-points, suggesting that C70-I could function 
similarly to ICS intervention in modulating MC responses to stimuli. 
 The gene and protein expression results led to examination of commonly used in 
vitro functional assays to compare two ICS, fluticasone and budesonide, to C70-I as a 
possible alternative to traditional asthma-ICS regulated therapy. Being that both 
compounds were capable of mediating the phosphatase DUSP1, we sought to discover if 
C70-I could be a successful candidate for modulating MC-degranulation and cytokine 
production. Specifically, optimal doses of all three interventions, fluticasone, budesonide, 
and C70-I result in significant inhibitions of degranulation by 55%, 48%, and 68% 
respectively, with fullerenes being nearly 20% more effective than traditional ICS 
treatments. These results were paralleled in GM-CSF cytokine production, where optimal 
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concentrations of fluticasone and budesonide inhibit release by 63% and 57% 
respectively, the same concentration of C70-I revealed nearly 30% greater inhibitions with 
significant reductions in cytokine production by 78%. In light of the degranulation and 
cytokine release assays, fullerenes may be an alternative to traditional ICS treatment. 
Overall, the fullerene intervention was capable of providing statistically significant 
reductions in MC-mediator release when compared to ICS treatment at the lower 
concentrations evaluated (10rg M). In situations of persistent asthma, patients are often 
given a dual-therapy of ICS and LABA. Therefore, it was considered important to 
evaluate the ability of C70-I to synergize with LABA. Consequently, these strategies 
mirrored those commonly observed in combinatory therapies of ICS/LABA. Such that 
C70-I co-incubation with the LABA, salmeterol, resulted in increased inhibitions 
compared to fullerene mono-therapy. The synergistic effects were similar to those in the 
ICS/LABA dual-therapeutic strategy, fluticasone/salmeterol, or budesonide/salmeterol, 
while not statistically significant, repeatedly revealed enhanced inhibition of 
degranulation between 4% and 10% respectively when compared to the mono-therapeutic 
approaches. C70-I combinatory therapies with salmeterol resulted in nearly a 10% 
increase in inhibition of degranulation compared to C70-I alone. These same trends were 
observed in cytokine production. Taken together, each of these results provides a 
heretofore undiscovered mechanism for controlling asthma using novel water-soluble 
fullerenes that are functionally similar to the present first-line treatment method, ICS. 
 Further studies will be required to understand how C70-I functions to increase 
DUSP1 levels after pretreatment; however it is proposed that C70-I offers some 
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protective qualities that prevent DUSP1 ubiquitination and subsequent activation-induced 
degradation. Following MC-activation, untreated cells displayed a rapid increase in 
DUSP1 production, a production that diminishes nearly 95% after two hours and 100% 
after four hours. However, the duration of this spike in production persists significantly 
longer in C70-I treated MC as displayed in Figure 6.1C. It is proposed that C70-I can 
prevent proteolysis degradation of the phosphatase, allowing it to act on MAPK well into 
')K#B/(?'#,A.%?#'.)D($,.)/*#R).B#7-;<=0#L(?#%AA/?.'#,?%#*/R#A/-('%C#/*#(*C%?'.,*C)*+#
what C70-I interacts with directly or if it is indirectly reducing ubiquitination through 
another mechanism, possibly reduced oxidative stress as has been demonstrated in other 
cell types [201]. 
 In conclusion, these studies reveal that strategically functionalized fullerene 
nanomaterials, like ICS, can control human lung MC mediator release through a DUSP1-
mediated mechanism. However, unlike ICS, their efficacy is not mediated through the 
glucocorticoid receptor. Since the fullerenes are taken up by MC via endocytosis, this 
may prove beneficial in patients with receptor mutations, who subsequently fail to 
respond to ICS treatment. These findings show that using water-soluble fullerenes with 
side-chain moieties such as C70-I could be pursued as a non-steroidal based therapy for 
patients that fail to respond clinically or respond adversely to ICS treatment. 
Additionally, these findings may not only provide a more robust controller therapy for 
patients with asthma, but a therapy with reduced adverse effects commonly associated 
with ICS treatment. 
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CHAPTER VI 
INHIBITION OF INFLAMMATORY ARTHRITIS USING FULLERENE 
NANOMATERIALS 
 
VI.1 Introduction 
Oxygen metabolism has an important role in the pathogenesis of inflammatory 
arthritis and therefore therapies that target its dysregulation have been investigated as 
potential treatments. Reactive oxygen species produced in the course of cellular oxidative 
phosphorylation, and by activated phagocytic cells during oxidative bursts, exceed the 
physiological buffering capacity and result in oxidative stress [202, 203]. Various forms 
of antioxidant therapy have demonstrated promising results in experimental arthritis 
models [204-208]. The polyphenolic fraction of green tea containing potent antioxidants 
reduces symptoms of collagen-induced arthritis [209]. A traditional Mediterranean diet 
relatively high in antioxidants improved RA disease activity and functional status after 
three months compared with a standard 'Western' diet [210]. In a separate study of 
patients with RA, antioxidant supplementation with vitamin A, E, and C increased 
plasma antioxidant levels with a corresponding decrease in malondialdehyde, a marker of 
oxidative stress; however, a clinical response was not reported [211]. Carvedilol, an 
adrenergic antagonist with antioxidant/anti-inflammatory properties effectively 
suppressed inflammation in two arthritis models [204]. More recently however, it was 
shown that water-soluble C60 fullerene prevents degeneration of articular cartilage in 
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osteoarthritis (OA) in rabbits [212] but no studies have examined fullerenes in 
inflammatory arthritis. 
The cellular interplay leading to inflammatory arthritis is complex. The synovium 
of many patients with rheumatoid arthritis (RA) exhibits an increase in the number of 
synovial mast cells (MC), in some cases representing 5% or more of the expanded 
population of total synovial cells [38, 213]. The number of accumulated MC differs 
substantially from patient to patient, in general varying directly with the intensity of joint 
inflammation [214]. Accompanying the increased numbers of MC, their mediators are 
also present at higher concentrations in the synovial fluid of inflamed human joints. 
These mediators include histamine, tryptase, and TNF-1#,$$#?%,C)$>#%$)-).%C#A?/D#9S#
upon exposure to various immunological and non-immunological stimuli [26, 215, 216]. 
TNF-1#,-.)&,.%C#'>*/&),l fibroblasts contribute to the initiation and perpetuation of 
inflammatory arthritis [217]. Several studies suggest that synovial fibroblasts demonstrate 
changes in morphology and function in RA patients through stimulation of both 
inflammation and tissue damage [218]. Lastly, osteoclasts are cells of the 
monocyte/macrophage lineage that are directly responsible for the bone destruction in 
inflammatory arthritis; therapies that reduce osteoclast function are being investigated as 
treatments for patients with inflammatory arthritis [219]. Reactive oxygen species act as 
intracellular signaling molecules in the regulation of RANKL-dependent osteoclast 
differentiation involving NF-!B [220-223]. In short, a clear connection exists between 
oxidative stress and the underlying mechanisms leading to inflammatory arthritis.   
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7($$%?%*%'#/?#o"(-T>H,$$'p#,?%#/*%#-$,''#/A#*,*/D,.%?),$'#.B,.#?%E?%'%*.#.B%#.B)?C#
allotrope (different structural modifications and arrangements of the same chemical 
elements) of carbon. Previous studies have demonstrated that fullerene derivatives can 
stabilize human MC depending on the structure of the chemical moieties added to the 
carbon cage [20, 22]. Given that fullerene derivatives have general anti-inflammatory 
properties through reductions in ROS levels and the blunting of the NF-!B signaling 
pathway [15, 20, 32, 48] it was hypothesized fullerene derivatives could ameliorate 
inflammatory arthritis. To test this hypothesis, a panel of water soluble fullerene 
derivatives were developed and tested them in vitro for their ability to alter mediator 
release from arthritis-inducing cells including MC and synovial fibroblasts from RA 
patients, as well as their effect on human osteoclast formation. The best candidates were 
selected for their ability to attenuate inflammatory arthritis in vivo using the K/BxN 
autoimmune model for arthritis and the CIA model for arthritis [44, 53]. It is 
demonstrated that the ability of fullerene derivatives to inhibit inflammatory cell 
mediator release was dependent on the moieties added to the carbon cage. The ability to 
inhibit in vitro mediator release translated to in vivo efficacy only in the K/BxN induced 
mice (regardless of the presence of MC). Collagen-induced arthritic mice showed no 
reductions in disease onset or progression when treated with fullerene derivatives.  
The ability of the fullerene derivatives to localize to inflamed joints was 
demonstrated using dye-conjugated fullerene derivatives which did not accumulate in 
other organs. Thus, our results suggest rationally designed fullerene derivatives may 
provide an effective therapeutic option for the treatment of inflammatory arthritis by 
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targeting ROS to prevent stimulation of pro-inflammatory cytokines, osteoclast 
formation, and stabilizing critical cells involved in RA progression. 
VI.2 Methods 
VI.2.1 Fullerene derivatives 
A panel of fullerene derivatives was synthesized at Luna Innovations and 
characterized for particle size using dynamic light scattering (Malvern Instruments, 
Zetasizer Nano ZS, Westborough, Massachusetts, USA), qNano (Izon Science, qNano, 
Cambridge, Massachusetts, USA) and nano particle tracking analysis, (Malvern 
Instruments, Nanosight LM10, Westborough, Massachusetts, USA), zeta potential 
(Malvern Instruments, Zetasizer Nano ZSP, Westborough, Massachusetts, USA), NMR 
(Agilent Technologies, 400 Mhz NMR Spectrometer, Santa Clara, California, USA), and 
FT-IR (Agilent Technologies, Varian 670 FT-IR, Santa Clara, California, USA). A 
representative physiochemical characterization schematic for the two fullerene 
derivatives used for the in vivo studies (TGA and ALM) is shown in [32, 48]. 
VI.2.2 Inflammatory mediator release from BMMC and human MC 
The activation of MC through F-;#?%-%E./?'#)'#/*%#-/*'.).(%*.#.B,.#C?)&%'#
)*A$,DD,./?>#,?.B?).)'0#]*$)T%#E?)D,?>#B(D,*#9SG#D/('%#9S#%KE?%''#7-;<===#,*C#D,>#
be stimulated to release mediators via this receptor in culture, although activation is 
-/*'.?,)*%C#H>#.B%#)*B)H)./?>#?%-%E./?#7-;RII [193]. Thus, BMMC were generated from 
7-;<==-deficient mice [44]. Cells were incubated with or without fullerene derivatives 
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/&%?*)+B.#qbc#d+`D$Y#[22]], washed and rat anti- 7-;<==`===#2O0enOG#b d+`D$6#,CC%C#A/?#2 
h. Immune complex (IC) stimulation was mimicked by the addition of donkey anti-rat 
(DAR; 1 µg/ml) added for 30 min (degranulation) or 24 h (cytokine) and cellular lysates 
prepared [224] collected and IL-bj#D%,'(?%C#(')*+#@h=4^#,'#C%'-?)H%C#[22]. Human 
connective tissue MCTC [193] were generated from skin and stimulated with immune 
complexes (IC) and mediator release measured as described [194]. Initial experiments 
C%.%?D)*%C#/E.)D,$#-/*-%*.?,.)/*'#/A#=S#A/?#B(D,*#9S#D%C),./?#?%$%,'%#R,'#f0f#d+`D$#
,*.)H/C>#R).B#c0bP#d+`D$#[Z-BSA (not shown). 
VI.2.3 Synovial fibroblast cytokine production 
Human fibroblasts (PC37303A1-S-Passage 1) from the synovium of RA patients 
(n=5) having joint replacement surgery (Asterand, Detroit, Michigan, USA) were plated 
in triplicate on a 96 well plate using RPMI complete medium. Cells were incubated 
overnight with or without fullerene derivatives at various concentrations, washed, and 
activated with or without 10 ng/ml of TNF-1#A/?#bO#B. The supernatants (in triplicate) 
were assayed for IL-6 and IL-8 using ELISA [105].   
VI.2.4 Osteoclast differentiation  
Human osteoclasts were obtained from peripheral blood mononuclear cells 
(PBMC) as described previously [225]. Mononuclear cells were cultured in complete 
DMEM containing RANKL (25 ng/ml) and M-CSF (25 ng/ml). Fullerene derivatives 
were added at varying concentrations and remained in the medium until the end of the 
experiment (eight days). Cells were washed, cytocentrifuge preparations made, and 
 
!
100 
analyzed for tartrate resistant acid phosphatase (TRAP) activity by cytochemistry (Sigma 
Aldrich, Acid Phosphatase Leukocyte assay, St. Louis, Missouri, USA). At eight days 
multinucleated cells containing three or more nuclei were counted. TRAP-positive cells 
containing three or more nuclei were considered to be differentiated osteoclasts. 
Experiments were done in triplicate, 25 microscopy fields at 40! magnification were 
evaluated for each sample. Quantitation of osteoclasts TRAP staining was performed 
using the infrared imaging analysis (Li-Cor Biosciences, Odyssey® Imaging CLx 
System, Lincoln, Nebraska, USA). 
VI.2.5 Measuring NF-!B levels using in-cell Western  
Human MC were plated in triplicate in 96-well plates and incubated as above with 
fullerene derivatives, washed, and activated with or witho(.#7-;<#'.)D($,.)/*#A/?#Oe#B as 
above. After treatment, cells were fixed by adding formalin to a final concentration of 
3.7% formaldehyde and incubated at room temperature for 10 minutes. After fixation, the 
plates were washed with PBS then permeabilized (PBS containing 0.1% Triton-X-100) 
by washing three times for 10 min on a bench top shaker and finally rinsed once with 
PBS containing 0.1% Tween 20. Cells were blocked using 50 µL/well blocking buffer 
(Li-Cor Biosciences, Odyssey® Blocking Buffer, Lincoln, Nebraska, USA) for one hour 
,.#?//D#.%DE%?,.(?%0#Z?)D,?>#,*.)H/C)%'G#j-Actin (1:1000) (Cell Signaling Technology, 
Danvers, Massachusetts, USA) and NF-!B (1:500) (Cell Signaling Technology, Danvers, 
Massachusetts, USA), incubated overnight at 4°C using 20 µL/well, washed three times 
with 100 µL/well PBS-Tween, and centrifuged at room temperature. Secondary 
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antibodies were prepared as for Western blotting with a few modifications: IRDye 
680CW and 800 CW conjugates of goat-anti-mouse-IgG (Li-Cor Biosciences, Lincoln, 
Nebraska, USA) were used at 1 1000 dilution for detection of antibody targets in the 800 
and 700 nm channels (green and red respectively). Plates were incubated with 20 µL/well 
secondary antibody solutions for 1.5 h at room temperature in the dark, washed three 
times for 10 min with PBS-Tween at room temperature, and filled with 50 µL/well of 
PBS to reduce surface disturbances when scanning. The 800-channel antibody signals 
were normalized to the 700-channel signals derived from IR-680 conjugated secondary. 
Background control wells were prepared by omitting primary antibodies, IRDye 680CW 
and IRDye 800CW (ie secondary only, Li-Cor Biosciences, Lincoln, Nebraska, USA). 
Plates were scanned and analyzed using an Odyssey® IR CLx system using the 
Odyssey® imaging software 3.0 (Li-Cor Biosciences). Scan settings were high image 
quality, 169 µm resolution, intensity 6.0 for the 700-channel, and 6.0 for the 800-channel 
with an offset of 4.0 mm. For signal quantification, antibody signals were analyzed as the 
average 800-channel integrated intensities from duplicate wells normalized to the 700-
channel signal integrated intensity to correct for well-to-well variations in cell number. 
Results are expressed as percent inhibition of the NF-!B responses (means ± standard 
errors of the mean) compared to vehicle-treated controls. 
VI.2.6 Mitochondrial membrane potential 
^-.)&%#D)./-B/*C?),#R).B#B)+B#D%DH?,*%#E/.%*.),$#2z{D6#,--(D($,.%#.B%#
lipophilic cationic probe 5,5',6,6'-tetrachloro-1,1',3,3'-
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tetraethylbenzimidazolcarbocyanine iodide (JC-1) in aggregates, which are red, whereas, 
)*#.B%#D)./-B/*C?),#R).B#$/R#z{D#2)*,-.)&%6G#\S-1 stays in a monomeric, green form 
[226, 227]. This renders the red:green ratio, a sensitive indicator of the mitochondrial 
z{D#-B,*+%'G#,*C#)*C)-,.%'#-%$$($,?#<L4#E?/C(-.)/*0#8B%#-B,*+%#)*#.B%#D)./-B/*C?),$#
membrane potential was measured in fullerene derivative-treated human MC using JC-1 
as previously described [228]. Cells (5x105/500 µl) were incubated overnight with 
fullerene derivative as above, washed, loaded with 2 µM JC-1 for 15 min, and activated 
as above. After cell stimulation, the green fluorescence (the monomeric JC-1) and red 
fluorescence (JC-1 aggregates) were measured using the FL-1 and FL-2 channels, 
respectively, with flow cytometry (Becton Dickinson, FACSCalib(?XG#@,'.#<(.B%?A/?CG#
New Jersey, USA). 
VI.2.7 Reactive oxygen species measurements 
Mast cells were incubated overnight with fullerene derivatives, washed, and 
incubated for 30 min with 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, final 
concentratio*#/A#V#d960#[%K.G#-%$$'#R%?%#R,'B%C#,*C#?%'('E%*C%C#)*#A?%'B#D%C),G#E$,-%C#
in a cuvette and activated with IC as above for 50-100 s. ROS fluorescence intensity was 
measured at the 523 nm wave length over a 12 minute time interval using 
spectrophotometry (Perkin Elmer, LS55 Luminescent Spectrometer, Waltham, 
Massachusetts, USA). All samples were measured in duplicate and performed at least 
three times.  
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VI.2.8 Odyssey imaging of fullerene derivatives in vivo 
To track the fate of fullerene derivatives in vivo an IRDye 800CW conjugated to 
ALM using a protocol similar to the one described [21]. These dyes are used in 
conjunction with the Xenogen imaging system and have been widely used for bio-
distribution studies [229]. The success of the conjugation and removal of free dye was 
verified using MALDI-MS (Bruker Corporation, Billerica, Massachusetts, USA) and 
absorption spectra.  Live mice with or without full-blown disease (K/BxN; day 14) were 
injected with various concentrations of the ALM-dye and whole body images obtained 
over 24 h.  
VI.2.9 Inflammatory arthritis 
A critical functional role for MC cells in arthritis pathogenesis has been suggested 
in K/BxN serum transfer arthritis [44] while more recent studies using a Kit-independent 
model for MC-deficiency were fully susceptible to antibody-induced autoimmune 
arthritis, as Kit mutations affect numerous cell types of both immune and non-immune 
origin [230]. To this end, Cre-mediated mast cell eradication (Cre-master) mice are used 
to obviate the deleterious effects associated with Kit mutated mice. To examine the 
therapeutic effects of ALM (a liposome encapsulated C70 fullerene) and TGA (a water-
soluble C70 A($$%?%*%#-/*v(+,.%C#R).B#A/(?#+$>-/$)-#,-)C'6G#y`"K[#'%?(D#2bOV#d$6#R,'#
)*v%-.%C#)*.?,E%?)./*%,$>#2)E6#.B%#C,>#,A.%?#A($$%?%*%#C%?)&,.)&%'#2ec#d+`bcc#d$#Z"46#R%?%#
injected i.p in C57BL/6 or Cre-master mice (8 weeks). The next day mice were injected 
again R).B#'%?(D#2bOV#d$60#7($$%?%*%#C%?)&,.)&%'#/?#Z"4#-/*.?/$'#R%?%#)*v%-.%C#)0E0#%&%?>#
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/.B%?#C,>#2ec#d+`bcc#d$#Z"46#.B?/(+B/(.#.B%#%KE%?)D%*.#,*C#.B%#'R%$$)*+#)*#%,-B#,*T$%#
was measured using calipers along with the clinical indices as described [44].  After 14 
days, serum was collected and assayed for TNF-1#$%&%$'#H>#@h=4^#2<|5#'>'.%D'G#
Minneapolis, Minnesota, USA). Mice were sacrificed, ankle sections removed, and 
sections scored as described below. Animal studies for the Cre-Master mice were 
approved by the Dana Farber Cancer Institute. 
To examine fullerene derivatives in the collagen-induced arthritis (CIA) model 
[231] DBA/1 mice, bovine type II Collagen (CII; MD Bioproducts, St Paul, Minnesota, 
USA) was dissolved in 10 mM acetic acid at a 4 mg/ml by stirring overnight at 4°C, 
,CC%C#./#,*#%J(,$#&/$(D%#/A#-/DE$%.%#7?%(*CF'#,Cv(&,*.#24)+D,#^$C?)-BG#4.#h/()'G#
Missouri, USA), and homogenized as described [232]. To induce CIA, 8-week-old 
female DBA/1 inbred mice (Harlan Laboratories, Dublin, Virginia, USA) were injected 
)*.?,C%?D,$$>#,.#.B%#.,)$#H,'%#R).B#bcc#}$#S==#)*#S7^0#7($$%?%*%'#2ec#d+`bcc#d$6#/?#Z"4#
were injected i.p. before disease induction and every other day after the first collagen 
injection. The animals received another injection of CII in CFA at the right hind paw two 
weeks after the primary immunization. Ankle and paw swelling was measured along with 
the clinical indices every other day. After four weeks, mice were sacrificed, serum 
collected, and histochemistry performed on ankles using H&E staining (IHC World, 
Woodstock, Maryland, USA). All animal studies for the CIA model were approved by 
University of North Carolina at Greensboro institutional review board. 
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VI.2.10 Disease analysis 
Several parameters of disease were analyzed to determine efficacy of treatment 
[44, 233]. The clinical index for each paw/ankle was measured, blinded to treatment 
group, as follows: 0 = no evidence of inflammation; 1 = subtle inflammation (metatarsal 
phalanges joints, individual phalanx, or localized edema); 2 = easily identified swelling 
but localized to either dorsal or ventral surface of paw/ankle; and 3 = swelling on all 
aspects of paw/ankle. Maximum score = 12.  Quantitative arthritic scores of each mouse 
(paws and ankles) were measured and expressed as the sum of the measured scores of 
four limbs. Here, actual swelling of the joint is measured using calipers. The degree of 
swelling in normal hind limbs (between 120-150 mm) and front limbs (between 110-130 
mm) is measured every other day starting one day before injections, averaged, and 
compared statistically to fullerene derivatives treated animals. Histology (H&E) of 
paw/ankle sections were analyzed for synovial hyperplasia, pannus formation, and 
inflammatory cellular infiltrate. Cytokine measurements (TNF-1G#=h-1) were measured as 
described [105] using sera from treated and untreated mice. 
VI.2.11 Statistics 
Data are presented as mean ± standard deviation. Analysis of variance (ANOVA) 
with NewmanWKeuls post hoc test was used to compare the effects of fullerene 
derivatives on mediator release from MC and on inflammation in murine models with the 
significance for all tests set at P < 0.05.  
 
!
106 
VI.3 Results 
VI.3.1 The efficacy of fullerene derivative inhibition on inflammatory mediator release 
and osteoclast formation depends on functional moieties added to the carbon cage 
^#E,*%$#/A#ec#A($$%?%*%#C%?)&,.)&%'#R,'#.%'.%C#A/?#.B%#,H)$).>#./#)*B)H).#7-;#
receptor-dependent degranulation and cytokine production from human and mouse MC. 
Previous studies demonstrated a*#/&%?*)+B.#)*-(H,.)/*#R).B#bc#d+`D$#R,'#/E.)D,$#A/?#
9S#'.,H)$)a,.)/*#./#7-;<=-dependent [22] and -independent [234] stimulation and was 
thus used for these studies. Approximately 15% of the fullerene derivatives tested 
significantly (p<0.05) inhibited both degranulation and IL-bj#27)+(?%#6.1A-C). As 
C%D/*'.?,.%C#E?%&)/('$>#%K,D)*)*+#7-;<=-dependent mediator release [22], several 
fullerene derivatives exhibited inhibitory capabilities on both degranulation and cytokine 
E?/C(-.)/*#)*#7-;-stimulated BMMC (Figure 6.1A) and IC-stimulated human tissue-
derived MC (Figure 6.1B) which was dependent on the side chain moieties added to the 
carbon cage.  Cytokine release from TNF-1-challenged synovial fibroblasts was 
significantly inhibited by 25% for all fullerene derivatives tested (Figure 6.1C). The two 
most efficacious cytokine blockers (ALM and TGA) also inhibited the formation of bone 
resorbing osteoclasts (Figure 6.1D). Thus, fullerene derivatives inhibit critical parameters 
important for the pathologies associated with inflammatory arthritis as assessed by in 
vitro models.  
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Figure 6.1.  Fullerene Derivatives Reduce Degranulation and Cytokine Production 
from Synovial Fibroblast from RA Patients, Mouse BMMC, and Human MC 
(hMC), and Osteoclast Formation from Human PBMC.  Figure 6.1A shows FcURII-
*PKK#O\\M#)*<PZ/0.1#?)0L#QPKK.-.*.#1.-)G/0)G.A#7G.-*)EL0#$HI#JE:;K(4#,L.#*.a0#1/R#
anti-FcURII/III antibody 2.4G2 or isotype control was added followed by cross-
linking donkey anti-rat (DAR) F(ab)24#M.KKA#?.-.#<.*0-)QPE.1#/*1#3-hexosaminidase 
release or IL-1 production determined in supernatants or lysates, respectively. Data 
shown are means ± SE of triplicate samples that is representative of three 
experiments.  All data was statistically significant with P values < 0.05. In Figure 
6.1B tissue MC were )*<PZ/0.1#?)0L#QPKK.-.*.#1.-)G/0)G.A#$HI#JE:;K(#7G.-*)EL0[#
washed and preformed IgG anti-NP!NP-O&5#);;P*.#<7;6K.a.A#bX4X#JE:;K#/*0)-NP 
5Z#?)0L#I4H>#JE:;K#cY-BSA [194]], were incubated with MC for 30 min or 4 h. 
Supernatants and cell lysates were prepared for mediator release analysis as 
described. Data is expressed as mean ± SE from three individual experiments.  P 
values < 0.05 by ANOVA when experimental values are compared with the Ab-only 
control (not shown). Figure 6.1C shows fullerene derivatives can inhibit cytokine 
production from rheumatoid arthritis-derived synovial fibroblasts. Synovial 
fibroblasts from RA patients were preincubated with or without various fullerene 
derivatives (10 µg/ml) overnight, washed, and incubated with TNF-" (10 ng/ml for 
12 h). Supernatants were saved and cytokines measured in the supernatants. The 
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percent inhibition of the treated cells was calculated based on the release of 
cytokines from non- fullerene derivative treated cells. Figure 6.1D shows the ability 
for fullerene derivatives to inhibit osteoclast formation. Human PBMC were 
incubated without (negative) or with RANK ligand (30 ng/ml) and GMCSF (25 
ng/ml). After 1 h fullerene derivatives were added (10 µg/ml) and remained 
throughout.  To verify the differentiation of mononuclear cells to osteoclasts, after 
eight days of culture, cells were analyzed for tartrate resistant acid phosphatase 
(TRAP) activity by cytochemistry. The cells with the reddish color represent 
osteoclast formation and are quantified in the graph (bottom). Results are 
representative of two separate experiments. Magnification 40X.  
 
 
VI.3.2 Fullerene derivatives inhibit mitochondrial membrane potential, ROS production, 
and NF-!B activation. 
Unstable mitochondrial membrane potential regulates ROS production [235].  Our 
previous work strongly suggested that fullerene derivatives inhibited degranulation 
through a pathway involving mitochondrial signaling proteins [20] and ALM is 
specifically designed to target mitochondrial membranes [48]. However, no studies have 
examined the role of mitochondrial membrane potential or fullerene derivatives in IC 
mediator release from human MC. Given that increases in MC mitochondrial membrane 
potential closely paralleled degranulation and previous studies suggested mitochondrial 
signaling pathways were affected by fullerene derivatives, it was hypothesized that the 
inhibitory effect of fullerene derivatives on MC degranulation may involve modulation of 
the mitochondrial membrane potential response. Initial studies demonstrated that MC 
mitochondrial membrane potential was dependent on dose (Figure 6.2A) and time (Figure 
6.2B) of the degranulation stimulus using IC. As seen in Figure 6.2C, MC incubated with 
fullerene derivatives prior to challenge with optimal concentrations of IC demonstrated a 
decrease in mitochondrial membrane potential compared to untreated MC. ALM and 
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TGA also inhibited IC-induced increases in ROS activity (Figure 6.2D). Lastly, NF-!B, 
which regulates genes controlling the amount of ROS and TNF-1#)*#.B%#-%$$#[236, 237], 
was down-regulated in IC-treated MC pre-incubated with fullerene derivatives (Figure 
6.2E).  Thus, decreased MC cellular activation through IC is due in part to decreased 
mitochondrial membrane potential, ROS production, and NF-!B activation. Two of the 
overall best inhibitors of these parameters included ALM and TGA, which were chosen 
for further study. 
 
 
Figure 6.2.  Mitochondrial Membrane Potential Correlates with MC Degranulation 
Through FcUR Receptors and is Inhibited by Fullerene Derivatives. In Figure 6.2A, 
change in mitochondrial membrane potential as a function of the concentration of 
IC stimulus was assessed.  Human MCs were stimulated with graded concentrations 
of preformed IgG anti-NP/NP-BSA immune complexes as indicated for 10 min. As a 
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control, cells without JC-1 and cells with JC-1 plus NP IgG only (no antigen) were 
incubated in parallel. The above experiment is representative of two separate 
samples. The percent of degranulation from these cells was 23%, 32%, 39%, and 
45% respectively. Mitochondrial membrane polarization was quantified by 
cytofluorimetry (FL2 channel) using FACs analysis as described above. As seen in 
Figure 6.2B, change in mitochondrial membrane potential as a function of time with 
fixed concentration of IC stimulus was assessed.  Human MCs were stimulated with 
X4X#JE:;K#/*0)-cY#5Z#?)0L#I4H>#JE:;K#cY-BSA of preformed IgG anti-NP/NP-BSA 
IC for the indicated times. As a control, cells without JC-1 were incubated in 
parallel. In Figure 6.2C, Fullerene derivatives inhibit IC-induced increases in 
mitochondrial membrane potential. Mast cells were incubated overnight with ALM 
or TGA (10 µg/ml) or media only. The next day cells were challenged with media 
containing JC-1 probe for 10 min at 37°C with or without IC (as in A).  After 10 min 
cells were washed with cold PBS, centrifuged and the JC-1 aggregates detected 
using the FL2. The above experiment is representative of three separate samples. As 
shown in Figure 6.2D fullerene derivatives inhibit IC-induced elevations in 
intracellular ROS levels. Mast cells were incubated overnight with fullerene 
derivatives, washed and DCF-DA added to cells for 30 min at 37
o
C. After washing 
cells were activated with optimal concentrations of IC and the fluorescence intensity 
measured at 525 nm after establishing baseline. Figures show representative 
numbers from duplicate samples for each condition and are representative of three 
separate MC cultures. Figure 6.2E shows that fullerene derivatives can block FcU 
receptor mediated activation of the MC transcription factor NF-!B. Mast cells were 
incubated with or without fullerene derivatives (10 µg/ml) overnight, washed, and 
challenged with IC for 24 h. After washing, in-cell Westerns were performed using 
the manufacturers protocol. Control wells (those without primary antibodies) were 
reserved as a source for background well intensity.  Further controls were cells 
incubated without fullerene derivatives or IC. Results represent results from two 
separate experiments.  
 
VI.3.3 ALM targets the inflamed synovial joints, but not organs, in vivo. 
In order to determine the bio-distribution of fullerene derivatives, in vivo 
experiments were performed using ALM conjugated to an IR-800 dye (ALM-IR-800). As 
seen in Figure 6.3, at seven days after serum (Figure 6.3A) or vehicle (Figure 6.3B) 
injection, during the peak symptom scores, ALM is clearly visible six hours post 
injection in the joints of mice with inflammatory arthritis. In contrast, control mice 
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without inflammatory arthritis receiving the same dose of fullerene-dye conjugates did 
not demonstrate fullerene-dye accumulation in the joints. These data confirm that ALM is 
-,E,H$%#/A#D)+?,.)*+#,*C#,--(D($,.)*+#R).B)*#.B%#v/)*.'#/A#D)-%#R).B#o,-.)&%p#
inflammatory arthritis where they are poised to inhibit the inflammatory cascade. 
Furthermore, organ evaluation (Figure 6.3C) revealed ratios reveal that very little 
fullerene derivative accumulated non-specifically throughout the body, as quantified in 
Figure 6.3D.  
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Figure 6.3.  ALM Targets Joints in Inflammatory Arthritis. In Figure 6.3A, non-
arthritic control (left) and arthritic (right) mice were injected intravenously with 50 
µg/300µl of ALM-IR800 and imaged 6 h K/0.-#PA)*E#0L.#N1RAA.Rd#);/E)*E#ARA0.;4##
Control mice (left) without inflammatory arthritis received the same concentration 
of fullerene-dye. Note the joint localization of the Dye-fullerene conjugate in the 
arthritic mouse.  Figure 6.3B shows whole mouse imaging and Figure 6.3C shows 
imaging of externalized organs performed 24 h after fullerene-dye injection (50 
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µg/300 µl). Fluorescence intensity is equally portrayed in all and represent a typical 
mouse out of three treated in parallel.  All of the images have undergone 
background noise subtraction. Figure 6.3D shows the quantification of fullerene dye 
concentration in representative organs from the mouse portrayed in Figure 6.3B-C.  
 
VI.3.4 ALM and TGA prevent inflammatory arthritis 
Given our results demonstrating the ability of fullerene derivatives to inhibit MC-
mediated [20, 22, 234] and general [15] inflammation, it was hypothesized that fullerene 
derivatives could inhibit the induction of inflammatory arthritis in vivo. When ALM and 
TGA were given before disease induction and during the course of disease onset, there 
was a striking inhibition of the K/BxN-induced disease pathology in both wild type 
(C57BL/6) and MC-deficient (Cre-master) mice.  After K/BxN serum transfer, PBS-
treated mice exhibited typical clinical arthritis as determined using clinical indices and 
quantitative ankle swelling measurements (Figures 6.4A and 6.4B). In contrast, fullerene 
derivative treated mice demonstrated a significant inhibition in both the clinical indices as 
well as ankle swelling measurements. Inflammation causing swelling was significantly 
inhibited at days 9 through 13 in wild-type mice and days 5 through 11 in MC-deficient 
Cre-master mice. Histochemically, the serum-treated mice demonstrated typical synovial 
hyperplasia, pannus formation, and inflammatory infiltrates (Figure 64C -top). In 
contrast, ALM treated animals had less evidence of clinical joint inflammation (Figure 
6.4C -middle) which was comparable to non-diseased animals (Figure 6.4C -bottom).   
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Figure 6.4.  Fullerene Derivatives Attenuate Inflammatory Arthritis in the K/BxN 
but not CIA Model. As shown in Figure 6.4A,  C57Bl/6 (n= 5 mice/group) mice were 
)*F.<0.1#?)0L#e:Oac#A.-P;#/A#1.A<-)Z.1#)*#\.0L71A4#,f5#7-#5T\#$gI#JE:HII#hK(#
were injected i.p. on Day 0, 2, and every second day. As a control 100 µl of PBS was 
injected in the control group.  Measurements were taken every second day by a 
blinded observer. Error bars, ±SEM. The * indicates significant differences 
observed on that day in fullerene derivatives compared to non-fullerene-treated 
mice (see text). Figure 6.4B shows representative ankle sections from K/BxN treated 
mice without ALM (left) or with ALM (middle). Control mice not serum challenged 
/-.#AL7?*#7*#0L.#-)EL04#$&</K.#Z/-A[#DI#J;(4#+)EP-.#6.4C shows disease pathogenesis 
in Cre-Master mice (n= 10 mice/group) with and without fullerene derivative 
therapy. As shown in Figure 6.4D, fullerene derivatives inhibit serum TNF-" levels 
in the K/BxN model and prevent the joint erosion induced by inflammatory 
arthritis. Serum levels were obtained at peak symptoms (Day 14) from K/BxN 
models and TNF-" measured as described (CIA model revealed no significant 
reductions) (n = 5 mice per group). 
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The CIA model of inflammatory arthritis shares several pathological 
commonalties with RA, synovial hyperplasia, mononuclear cell infiltration, cartilage 
degradation, and plays a prominent role in joint destruction [231]. In contrast to the 
K/BxN model there was a small but not significant improvement in the fullerene treated 
animals compared to untreated animals when measuring ankle thickness and clinical 
indices (data not shown).   
Lastly, the levels of serum TNF-1#R%?%#')+*)A)-,*.$>#$/R%?#,.#C,>#be#)*#.B%#D)-%#
treated with TGA and ALM compared to those mice given vehicle (PBS) only injection 
(p=0.0009 and 0.01, respectively) in the K/BxN model (Figure 6.4D). However, there 
was no change in the levels of serum TNF-1#$%&%$'#)*#A($$%?%*%#C%?)&,.)&%'#.?%,.%C#,*C#
untreated animals in the CIA models (data not shown). These results suggest fullerene 
derivatives can inhibit inflammatory arthritis and may exert their anti-arthritic inhibitory 
effect in vivo by blocking TNF-1#E?/C(-.)/*0 
VI.3.5 Toxicological assessment of ALM and TGA 
In separate experiments high concentrations of ALM and TGA were injected 
under the same protocol as above except using 100 mg/kg. There was no significant 
increase in serum activity of ALT and AST between the untreated and ALM and TGA-
treated animals indicating no liver toxicity. In fact, both fullerene derivatives provided a 
small protective effect against the rise in AST/ALT levels in the K/BxN and CIA models. 
Additionally, serum creatinine levels were measured in order to assess kidney toxicity 
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[238].  These initial results suggest that ALM and TGA are not acutely toxic to the liver 
or kidney.    
VI.4 Conclusions 
The molecular events leading to the morbidity associated with arthritis is complex 
and involves a number of factors. Mast cells have been especially implicated in the 
disease process and preventing mediator release from these cells has been a target for 
therapeutic intervention [38, 239]. The initial impetus for these studies was the 
observation that certain fullerene derivatives can stabilize MC in vitro and in vivo. Thus, 
given the potentially important influence of MC on key processes within the chronically 
inflamed synovium, the hypothesis that fullerene derivatives could ameliorate 
inflammatory arthritis was tested. It is shown that the efficacy of fullerene derivatives in 
this process is dependent on how the carbon core is derivatized with side chain moieties. 
Importantly, no organ accumulation or acute toxicity was detected when assessing liver 
and kidney function using concentrations twenty times higher than needed for efficacy.   
The strategy for these studies was to first determine which fullerene derivatives 
inhibited human and mouse MC through arthritisWrelevant stimulation. In addition, the 
ability of fullerene derivatives to inhibit synovial fibroblast cytokine production and 
osteoclast development were considered important prerequisites for predicting in vivo 
efficacy [219, 240]. To this end, a panel of fullerene derivatives were tested for their 
,H)$).>#./#)*B)H).#9S#7-;R-mediated responses [241]. A clear structure-activity 
relationship between fullerene derivatives and inhibitory function was not defined. 
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However, in general, the fullerene derivatives that were most efficient at inhibiting MC 
mediator release had side chain moieties that induced maximum water solubility, a zeta 
potential between 37 and -146 mV, and particle sizes between 50 to 200 nM. Of these, 
both TGA and ALM have been shown previously to inhibit IgE-mediated degranulation 
and cytokine production [22] and in response to other non-IgE-mediated secretagogues 
[234]. The TGA (tetra-glycolic acid) is a C70 series with four carboxyl groups, which 
confers water solubility. It is postulated that the mechanism by which TGA exerts its 
effect via an interaction between the carboxyl groups and the electrons on the fullerene 
cage. To examine this point, a similar fullerene derivative that presented a triethylene 
glycol spacer between the carboxyl groups and the cage was prepared. TEG -TGA (-25 
mV zeta potential; 94 nM particle size) did not block MC mediator release nor did it 
interfere with cytokine release (not shown). This result is consistent with the hypothesis 
that proximity of the carboxyl groups to the cage is necessary for activity.  
The mitochondrial electron transport is the machinery that orchestrates one of the 
most fundamental of chemical processes; the generation of cellular energy from oxygen 
resulting in the fuel that supports all eukaryotic life. However, it is a highly sensitive 
process and, unbalanced, leads to the generation of free radicals or ROS which have been 
linked as a mechanism underlying many chronic human diseases including MC activation 
and inflammatory arthritis [47, 242]. ALM is a mitochondria targeting fullerene 
derivatives that has been previously shown to home to mitochondria and inhibit 
inflammation [15, 48]. ALM was designed to accumulate in the internal mitochondrial 
membrane bilayers positioned to neutralize superoxide molecules, reactive lipid radicals, 
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and radicals that have formed on transmembrane proteins at the site where they are 
generated. Subsequently, this is predicted to impact diseases whose pathologies stem 
from radical injury. 
  To this end both fullerene derivatives significantly block ROS production and 
mitochondrial membrane potential. While it has been shown previously that human MC 
C%+?,*($,.)/*#)*#?%'E/*'%#./#7-;<=#,*C#7-;-signaling involves ROS [58,59], it is not 
clear if blocking ROS directly blocks degranulation and cytokine production. Results 
B%?%#'(++%'.#.B,.#H$/-T)*+#<L4#(')*+#^h9#,*C#8n^#)*#?%'E/*'%#./#=S#2,*#7-;<==^-
dependent stimuli [194]) parallels inhibition of mediator release. This is in line with 
previous work suggesting that fullerenes interfere with the generation of mitochondrial-
derived ROS [51, 52, 243, 244]. It is also demonstrated that mitochondrial membrane 
potential is a critical determi*,*.#)*#B(D,*#9S#7-;<-mediated degranulation. While 
further studies are needed these data suggest that fullerenes inhibit MC through a 
mechanism involving the mitochondrial membrane potential and suggest a critical role of 
the mitochondria in human MC non-IgE mediator release.  
Nuclear factor-kappa B is involved in the pathophysiology of inflammatory and 
efforts to target its function through molecular targets in the pathway leading to its 
activation are underway [245-247]. This transcription factor induces both TNF-1#,*C#=h-
bj#+%*%#%KE?%'')/*#RB)-B#-,*#H/.B#)*#.(?*#,-.)&,.%#.B%#[7-!B pathway inducing an 
autocrine loop which perpetuates inflammation. Interestingly, some of the drugs for RA 
were shown to block either the NF-!B activation cascade or its action [245, 247, 248]. 
For example, gold-containing therapeutics, TNF-1#)*B)H)./?'G#,*C#D%.B/.?%K,.%G#,$$#
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regularly used for treating arthritis, can effect NF-!B function [249, 250].  Several 
fullerene derivatives, including ALM and TGA, inhibited IC-induced NF-!B activation in 
human MC. Current studies are examining what signaling molecules in the 
ROS/TNF/NF-!B pathway [237] are affected by fullerene derivatives.  
Arthritic joint tissues demonstrate a striking predilection for uptake of ALM.  
Indeed, this strong uptake may provide the basis of their efficacy in ameliorating arthritis.  
It was also demonstrated that fullerene derivatives inhibited the onset of arthritis in 
K/BxN serum transfer arthritis in C57Bl/6 mice.  However, there was a small but not 
significant improvement in the CIA model. The K/BxN model induces a rapid and severe 
synovitis dependent on neutrophils, MC, and macrophages.  A role for MC was revealed 
from studies in which two strains of mice deficient in this cell type, W/Wv and Sl/Sld, 
were resistant to disease induction following serum transfer [44]. Susceptibility to disease 
is restored in the W/Wv strain by MC engraftment. However, new research [230] has 
revealed that the K/BxN model, is not MC-dependent as the original findings may be a 
result of Kit mutations affecting multiple cell types. In contrast, the Cre-master model 
ablates MC numbers through a different mechanism: by targeted insertion of Cre-
recombinase into the MC carboxypeptidase A3 locus and subsequent Trp53-dependent 
MC depletion. Cre-mediated mice are fully susceptible to antibody-induced autoimmune 
arthritis. This suggests the inhibition seen with fullerenes possibly occurs due to the 
blocking of some component associated with the K/BxN serum transfer as this is the 
major difference in the two models suggesting a more robust and promiscuous pathway 
in which the fullerenes are reducing disease symptoms. Taken together, our results 
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suggest that fullerene derivatives block arthritis in certain mouse models that blocks some 
component of TNF-1#?%$%,'%#RB)-B#D,>#/?#D,>#*/.#)*-$(C%#9S#,-.)&,.)/*0#n)&%*#.B%#
vast differences in MC phenotypes and expression in the rodent vs. human systems [118] 
there may also be differences in the ability of fullerenes to inhibit MC from the two 
species. Further studies are needed to determine whether fullerenes may be a valid 
strategy for human arthritis intervention.   
As in other studies using purified and well characterized fullerene derivatives [49, 
198, 199] no liver or kidney toxicity was detected using repeated dosing of 
concentrations higher than that needed for in vivo efficacy [177]. The in vivo imaging 
studies also demonstrated a lack of uptake in other organs, which portends well for a 
favorable toxicity profile in clinical development of ALM. Of course, more advanced 
toxicity studies are needed to assess these two fullerene derivatives as is the case with 
any new therapeutic. 
In conclusion, it was demonstrated that not all fullerene derivatives exhibit the 
same ability to inhibit inflammatory mediator release from MC and synovial fibroblasts. 
Two fullerene derivatives were able to significantly block the onset of serum-induced 
arthritis in vivo leading to a blunted inflammatory response; however CIA-induced mice 
were refractory to fullerene treatment. More studies are needed to identify those structure 
activity relationships that are dependent on the moieties added to the fullerene carbon 
cage in order to define the precise mechanism by which these fullerene derivatives inhibit 
inflammatory disease.   
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CHAPTER VII 
FUTURE PERSPECTIVES 
 
Fullerenes and their unique properties can be beneficial to many modern medical 
applications; as they are composed entirely of carbon in a hollow sphere (without 
requiring a toxic metal catalyst), their functionalization (with chemicals to increase their 
hydrophilicity) or encapsulation (in carriers, i.e., as liposomes) allows for easy solubility 
in biologically suitable aqueous media. The innate properties of fullerenes render high 
antioxidant capacity at extremely small sizes that can be functionalized or tailored to 
accommodate a broad range of diagnostic and therapeutic applications. Recent 
developments and future research in the fullerene field could reveal numerous 
commercial applications spanning a broad spectrum: antiviral; anticancer; photo-
sensitizers; antioxidant activity; drug delivery and gene therapy; and highly sensitive-
targeted diagnostic applications.  
Current research in fullerenes could create significant strides in slowing or 
suppressing the progression of HIV infection to AIDS [251-253]. Mechanistically, their 
success as a potential antiviral application is based on the compounds unique geometry 
and high antioxidant activity. The compounds are capable of complexing and inhibiting 
the HIV protease with a relatively high structureWactivity relationship [251]. The 
fullerenes can spatially bind in the cavity (10 Å approximate diameter) regions of HIV 
protease tightly and prevent the release of water, subsequently inhibiting the active 
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regions of the protease [254]. The fullerenes strong affinity to bind to the enzymes active 
site results in significant inhibition of viral replication [252, 255].  
Fullerenes are also capable of being photoexcited and have, thus, been exploited 
as photosensitizers, whereby fullerenes can be conjugated with high affinity to specific 
proteins and nucleic acids. The photoirradiated fullerene is excited from its ground state 
and converted back via intersystem crossing, creating a highly toxic singlet oxygen 
species. Researchers have demonstrated that using photodynamic therapy, fullerenes 
could photosensitize specifically targeted cells, which could rapidly reduce cell viability 
[256]. This technique has also been modified to a theranostic approach utilizing 
gadolinium-containing endohedral fullerenes to selectively target, photosensitize and 
image tumor reduction over time [257].  
The potential for using fullerene-based medicines is substantial but concerns of 
toxicity have slowed the initial enthusiasm that surrounded their discovery. Only those 
studies using well--B,?,-.%?)a%CG#')*+$%#'E%-)%'G#I$%,C#-,*C)C,.%F#A($$%?%*%#A/?D($,.)/*'#
can provide meaningful information regarding potential toxicological effects. Such 
studies are needed as the state of research today with fullerenes is shaped by studies such 
,'#.B%'%#.B,.#,CC?%''#.B%#/H'%?&,.)/*#o.B,.#%K.?,E/$,.)/*#,-?/''#')D)$,?#*,*/E,?.)-$%'#R)$$#
be dependent upon surface chemistry and concentration which may affect the degree of 
,++$/D%?,.)/*#,*C#.B('#H)/$/+)-,$#%AA%-.'p#[258]. Thus, more thorough studies will serve 
as a building block in developing a database that links surface functionalization chemistry 
of fullerene compounds to biological function. Significant strides have been made 
throughout the last decade to help propel fullerenes as a functional platform to help solve 
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many modern medical limitations. However, the translation of successful research into 
market application will require more work to better understand uptake, biodistribution, 
absorption, lifetime, excretion and, ultimately, consumer safety of these nanostructures.  
The unique physical and chemistry properties, the decrease in production cost, 
increased scalability and broad range of potential medical applications have stimulated a 
lot of research within the industry. While initial toxicity concerns stalled progress, recent 
studies have shown limited evidence of any toxicity associated with these novel 
nanomaterials. In time the fullerene field will make strides in penetrating industry, but 
only when more thorough characterization and sufficient research is accomplished to 
address long-term, reproducible toxicological data will this fascinating class of molecules 
bring advances to modern medicine. 
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APPENDIX A 
 
 DESIGN SYNTHESIS OF ATCA 
 
 
 
Figure A.1.  Design Synthesis of ATCA.   
 
Top: PAPC and its oxidation product oxPAPC as CD36 ligands under 
myeloperoxidase (MPO)-H2O2-NO2- system. Bottom: structure of the ATCA TMS 
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derivative used in this study. To develop the CD36 ligands, PAPC (1-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphocholine or 1-hexadecanoyl-2-eicosatetra-V~Gf~Gbb~Gbe~-
enoyl-sn-glycero-3-phosphocholine) was oxidized by the myeloperoxidase (MPO)-H2O2-
NO2- system to generate oxidized PAPC (oxPAPC) which includes HOdiA-PC, KOdiA-
PC, HOOA-PC and KOOA-PC species. Briefly, 1 mg/ml PAPC solution of small 
unilamellar vesicles was prepared and oxidized by a mixture of 30 *9#9ZLG#bcc#d9#
glucose and 100 ng/ml glucose oxidase (generating H2O2), and 0.5 mM NaNO2 for 24 h 
at 37°C. The reaction was stopped by adding butylated hydroxyltoluene (BHT) and 
catalase. The oxPAPC lipids were extracted from the oxidized PAPC vesicles with 
chloroform three times. The combined organic phases were evaporated under nitrogen to 
dryness. Liquid chromatography was used to demonstrate the successful oxidation of 
PAPC and to quantify the ratio of oxidized lipids to those non-oxidized. The bioactive 
and oxidized PAPC lipids were used in the preparation of TMS-encapsulated liposomes. 
The final ATCA was made by mixing 20 parts of regular phosphocholine  lipids 
(DPPC), one part of oxPAPC and five parts of amphiphilic TMS, having one C18 
aliphatic chain and five short PEG polar groups] in chloroform under nitrogen and the 
mixture was evaporated to dryness under vacuum to form a thin film on the flask wall.  
The material was hydrated by sonicating the film materials in buffered saline (pH 7.4) 
using a bath sonicator under nitrogen. The crude liposomes were extruded three times 
with 400 nm, 200 nm, and 100 nm nucleopore membranes each to produce the final 
ATCA sample as a brownish suspension. The control sample has the same ratio of both 
amphiphilic TMS derivative and DPPC as ATCA (approximately 30,000-32,000 
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TMS/liposome), but do not contain any CD36 ligands. The incorporation of colored TMS 
derivatives in liposome bilayers was further confirmed by buoyant density test, where the 
functionalized TMS stayed associated with lipid bilayers on the top of a 40% sucrose 
cushion under high speed centrifugation conditions that typically precipitate any TMS 
materials if not tightly associated with lipid membranes. ATCA samples can be further 
purified by eluting them on a size exclusion Sephadex column to remove any lipids 
unincorporated in the liposome bilayer. The co-elution of lipids (DPPC and oxPAPC) 
with TMS derivatives further demonstrated their tight association in the bilayer structure. 
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APPENDIX B 
 
 DLS, ZETA POTENTIAL, AND RELAXIVITY OF LIPOSOME CONTROL AND 
ATCA 
 
 
 
Figure B.1.  DLS, Zeta Potential, and Relaxivity of Liposome Control and ATCA.  
 
A. ATCA (black) and liposome control (grey) were diluted 1:100,000 and either 
subjected directly for analysis, vortexed, or sonicated and vortexed to reduce 
agglomeration. Dynamic light scattering (DLS) and zeta potential values (Zetatrac, 
Microtrac Instrument) were used to assess the physical characteristics of the nanoparticle 
conjugates in solution. The size distribution profile of ATCA and control (no CD36 
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39.02 and -25.50 mV suggesting that the ATCA are extremely stable. The size 
distribution and zeta potential did not significantly change after vigorous vortexing or 
sonication. The relaxivity r1 of ATCA was calculated by a benchtop relaxometer and 
determined to be 75 mM-1s-1  B. Nanosight nanoparticle tracking of ATCA. ATCA was 
diluted as above and particle size distribution was measured (106 particles/ml) for 90 
seconds. The Nanosight nanoparticle tracking analysis instrument was used and revealed 
a mean particle size of 0.092 µm. The smaller size distribution for the Nanosight is a 
result of individualized particle distribution of size, whereas DLS results are volume 
based distribution of size. Volume based distribution results in larger particle size due to 
the fact that larger particles have higher volumes and thus heavily influences mean 
measurements. C. FTIR analysis of ATCA. Fourier transform infrared spectroscopy 
(FTIR) spectrum of TMS (green), Liposome control (red), and ATCA (black).  The 
presence of TMS inside the liposome was verified by the following peaks at 1093 (C-N), 
1361 (N-O), 1571 (N-O), and 3149 (O-H) cm-1. In the ATCA sample the peak at 1361 
cm-1 is broadened by the C-N bond. The N-O peak broadens the peak around 1400 cm-1.  
The 1571 cm-1 peak shows that a new bond type is present that did not exist in the 
liposome.  The O-H bond of the TMS slightly shifts the alcohol absorption peak to the 
right and broadens its appearance. Next, the presence of PAPC conjugated to the 
liposome was proven by the peaks at 1090 (PO2-) and 823 (P-O-C) as previously 
described. In the case the P-O-C bond the sharp peak at 823 cm-1 was broadened and for 
the PO2-  a shoulder was formed at 1090 cm-1 . 
